Nuvve Holding (NVVE) 10-Q/A 31 Mar 23 2022 Q1 Quarterly report (amended) Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 05, 2022
Document Information [Line Items]
Document Type	10-Q/A
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-40296
Entity Registrant Name	NUVVE HOLDING CORP.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-1617000
Entity Address, Address Line One	2468 Historic Decatur Road,
Entity Address, City or Town	San Diego,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92106
City Area Code	(619)
Local Phone Number	456-5161
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,969,086
Amendment Flag	false
Entity Central Index Key	0001836875
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NVVE
Security Exchange Name	NASDAQ
Warrants
Document Information [Line Items]
Title of 12(b) Security	Warrants to Purchase Common Stock
Trading Symbol	NVVEW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)		Mar. 31, 2022		Dec. 31, 2021
Current assets
Cash		$ 23,704,646	[1]	$ 32,360,520	[2]
Restricted cash	[2]	480,000		380,000
Accounts receivable	[2]	1,431,134		1,886,708
Inventories	[2]	9,328,206		11,118,188
Prepaid expenses and other current assets	[2]	1,685,008		1,036,645
Total Current Assets	[2]	36,628,994		46,782,061
Property and equipment, net	[2]	572,499		356,194
Intangible assets, net	[2]	1,446,218		1,481,077
Investment	[2]	670,951		670,951
Right-of-use operating assets	[2]	3,397,270		3,483,042
Financing receivables	[2]	238,624		138,161
Security deposit, long-term	[2]	3,057		3,057
Total Assets	[2]	42,957,613		52,914,543
Current Liabilities
Accounts payable	[2]	3,216,560		5,738,873
Accrued expenses	[2]	3,564,224		2,874,018
Deferred revenue	[2]	690,868		719,771
Operating lease liabilities - current	[2]	254,057		41,513
Other liabilities	[2]	108,384		110,574
Total Current Liabilities	[2]	7,834,093		9,484,749
Operating lease liabilities - noncurrent	[2]	3,319,734		3,441,642
Warrants liability	[2]	4,792,475		9,543,000
Derivative liability - non-controlling redeemable preferred shares	[2]	433,000		511,948
Other long-term liabilities	[2]	17,283		18,860
Total Liabilities	[2]	16,396,585		23,000,199
Commitments and Contingencies	[2]
Mezzanine equity
Redeemable non-controlling interests, preferred shares, zero par value, 1,000,000 shares authorized, 3,138 shares issue and outstanding at March 31, 2022 and December 31, 2021; aggregate liquidation preference of $3,264,775 at March 31, 2022	[2]	3,063,365		2,901,899
Stockholders’ (Deficit) Equity
Common stock, $0.0001 par value, 100,000,000 shares authorized; 18,891,500 and 18,861,130 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	[2]	1,891		1,888
Additional paid-in capital	[2]	123,792,248		122,336,607
Accumulated other comprehensive income (loss)	[2]	99,762		113,446
Accumulated deficit	[2]	(97,568,191)		(92,937,863)
Nuvve Stockholders’ Equity (Deficit)	[2]	26,325,710		29,514,078
Non-controlling interests	[2]	(2,828,047)		(2,501,633)
Total Stockholders’ Equity (Deficit)	[2],[3]	23,497,663		27,012,445
Total Liabilities, Mezzanine equity and Stockholders’ Equity	[2]	42,957,613		52,914,543
Cumulative Preferred Stock
Stockholders’ (Deficit) Equity
Preferred stock, $0.0001 par value, 1,000,000 shares authorized; zero shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively		$ 0		$ 0	[2]
[1]See Note 2.[2]See Note 2.[3]See Note 2

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Temporary equity, par value (in Dollars per share)	$ 0
Temporary equity, shares authorized (in Shares)	1,000,000
Temporary equity, shares issued (in Shares)	3,138	3,138
Temporary equity, shares outstanding (in Shares)	3,138	3,138
Temporary equity, liquidation preference	$ 3,264,775
Preferred stock par value (in Dollars per share)	$ 0.0001
Preferred stock, shares authorized (in Shares)	1,000,000
Common stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in Shares)	100,000,000
Common stock, shares issued (in Shares)	18,891,500	18,861,130
Common stock, shares outstanding (in Shares)	18,891,500	18,861,130
Cumulative Preferred Stock
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in Shares)	1,000,000	1,000,000
Preferred stock, shares issued (in Shares)	0	0
Preferred stock, shares outstanding (in Shares)	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	[1]	Mar. 31, 2021
Revenue
Total revenue	$ 2,371,033		$ 799,032
Operating expenses
Cost of product and service revenue	2,142,312		127,228
Selling, general, and administrative	7,625,550		4,482,740
Research and development	2,135,575		1,262,950
Total operating expenses	11,903,437		5,872,918
Operating loss	(9,532,404)		(5,073,886)
Other income (expense)
Interest income (expense)	1,458		(597,549)
Change in fair value of warrants liability	4,776,000	[2]	421,830
Change in fair value of derivative liability	53,472		0
Other, net	(29,787)		(112,115)
Total other (expense) income, net	4,801,143		(287,834)
Loss before taxes	(4,731,261)		(5,361,720)
Income tax (benefit) expense	0		0
Net loss	(4,731,261)	[2],[3],[4]	(5,361,720)
Less: Net loss attributable to non-controlling interests	(100,933)		0
Net loss attributable to Nuvve Holding Corp.	(4,630,328)		(5,361,720)
Less: Preferred dividends on redeemable non-controlling interests	64,015		0
Less: Accretion on redeemable non-controlling interests preferred shares	161,466		0
Net loss attributable to Nuvve common stockholders	$ (4,855,809)		$ (5,361,720)
Net loss per share attributable to Nuvve common stockholders, basic (in Dollars per share)	$ (0.26)		$ (0.52)
Net loss per share attributable to Nuvve common stockholders, diluted (in Dollars per share)	$ (0.26)		$ (0.52)
Weighted-average shares used in computing net loss per share attributable to Nuvve common stockholders, basic (in Shares)	18,864,374		10,408,080
Weighted-average shares used in computing net loss per share attributable to Nuvve common stockholders, diluted (in Shares)	18,864,374		10,408,080
Products and services
Revenue
Total revenue	$ 2,253,784		$ 311,903
Grants
Revenue
Total revenue	$ 117,249		$ 487,129
[1]See Note 2.[2](1) See Note 2.[3]Note 2.[4]See Note 2

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	[2]	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (4,731,261)	[1],[3],[4]	$ (5,361,720)
Other comprehensive (loss) income, net of taxes
Foreign currency translation adjustments, net of taxes	(13,684)	[3]	116,749
Total Comprehensive loss	(4,744,945)		(5,244,971)
Less: Comprehensive loss attributable to non-controlling interests	(100,933)		0
Comprehensive loss attributable to Nuvve Holding Corp.	(4,644,012)		(5,244,971)
Less: Preferred dividends on redeemable non-controlling interests	(64,015)		0
Less: Accretion on redeemable non-controlling interests preferred shares	(161,466)		0
Comprehensive loss attributable to Nuvve common stockholders	$ (4,418,531)		$ (5,244,971)
[1](1) See Note 2.[2]Note 2.[3]See Note 2[4]See Note 2.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($)		Total		Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Non-controlling Interests	Series A Convertible Preferred Stock Preferred Stock
Balances (in Shares) at Dec. 31, 2020				26,162,122					16,789,088
Balances at Dec. 31, 2020		$ (880,710)		$ 2,616	$ 19,650,659	$ (77,841)	$ (20,457,823)		$ 1,679
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of shares due to merger capitalization (in Shares)				(17,039,126)					(16,789,088)
Conversion of shares due to merger capitalization		0		$ (1,704)	3,383				$ (1,679)
Balances, as previously reported and effect of reverse recapitalization (in Shares)				9,122,996
Balances as previously reported and effect of reverse recapitalization		(880,710)		$ 912	19,654,042	(77,841)	(20,457,823)
Beneficial conversion feature - convertible debenture		427,796			427,796
Conversion of convertible debenture (in Shares)				544,178
Conversion of convertible debenture		3,999,435		$ 54	3,999,381
Repurchase of shares (in Shares)				(600,000)
Repurchase of common stock from EDF		(6,000,000)		$ (60)	(5,999,940)
Assumption of private warrant liability from Newborn		(1,253,228)			(1,253,228)
Merger recapitalization, net of share redemption of issuance costs (in Shares)				8,060,418
Merger recapitalization, net of share redemption of $18,629 and issuance costs of $5,979,675		51,751,363		$ 806	51,750,557
Issuance of common shares (in Shares)				208,532
Issuance of common shares		2,085,320		$ 21	2,085,299
PIPE offering, less issuance costs (in Shares)				1,425,000
PIPE offering, less issuance costs of $2,500		14,247,500		$ 143	14,247,357
Notice of exercise of put option		(2,000,000)			(2,000,000)
Stock-based compensation		262,105			262,105
Currency translation adjustment		116,749				116,749
Net loss		(5,361,720)					(5,361,720)
Balances (in Shares) at Mar. 31, 2021				18,761,124					0
Balance at Mar. 31, 2021		57,394,610		$ 1,876	83,173,369	38,908	(25,819,543)		$ 0
Balances (in Shares) at Dec. 31, 2020				26,162,122					16,789,088
Balances at Dec. 31, 2020		(880,710)		$ 2,616	19,650,659	(77,841)	(20,457,823)		$ 1,679
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		27,200,000
Balances (in Shares) at Dec. 31, 2021	[1]			18,861,130
Balance at Dec. 31, 2021	[1]	27,012,445	[2]	$ 1,888	122,336,607	113,446	(92,937,863)	$ (2,501,633)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options and vesting of restricted stock (in shares)	[1]			30,370
Exercise of stock options and vesting of restricted stock	[1]	3		$ 3
Stock-based compensation	[1]	1,455,641			1,455,641
Currency translation adjustment	[1]	(13,684)	[3]			(13,684)
Preferred dividends - non-controlling interest	[1]	(64,015)						(64,015)
Accretion on redeemable non-controlling interests preferred shares	[1]	(161,466)						(161,466)
Net loss	[1]	(4,731,261)	[3],[4],[5]				(4,630,328)	(100,933)
Balances (in Shares) at Mar. 31, 2022	[1]			18,891,500
Balance at Mar. 31, 2022	[1]	$ 23,497,663	[2]	$ 1,891	$ 123,792,248	$ 99,762	$ (97,568,191)	$ (2,828,047)
[1]See Note 2[2]See Note 2.[3]Note 2.[4](1) See Note 2.[5]See Note 2.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) (Parenthetical)	3 Months Ended
	Sep. 30, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Merger recapitalization, net of share redemption	$ 18,629
Issuance costs	5,979,675
Less issuance costs	$ 2,500

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2022		Mar. 31, 2021	Dec. 31, 2021		Dec. 31, 2020
Operating activities
Net loss	$ (4,731,261)	[1],[2],[3],[4]	$ (5,361,720)	$ 27,200,000		$ 4,700,000
Adjustments to reconcile to net loss to net cash used in operating activities
Depreciation and amortization	67,302	[1]	41,390
Share-based compensation	1,455,644	[1]	262,105
Beneficial conversion feature on convertible debenture	0	[1]	427,796
Accretion of discount on convertible debenture	0	[1]	116,147
Change in fair value of warrants liability	(4,776,000)	[1],[4]	(421,830)
Change in fair value of derivative liability	(53,472)	[1]	0
Loss on disposal of asset	0	[1]	1,405
Gain on extinguishment of PPP Loan	0	[1]	(764)
Noncash lease expense	178,849	[1]	0
Change in operating assets and liabilities
Accounts receivable	454,849	[1]	151,204
Inventory	1,789,982	[1]	(1,853,640)
Prepaid expenses and other assets	(915,356)	[1]	(1,656,880)
Accounts payable	(2,521,672)	[1]	1,703,781
Accrued expenses	624,722	[1]	3,723,729
Deferred revenue	(23,476)	[1]	233,426
Net cash used in operating activities	(8,449,889)	[1]	(2,633,851)
Investing activities
Proceeds from sale of property and equipment	0	[1]	8,107
Purchase of property and equipment	(250,861)	[1]	0
Net cash (used) provided in investing activities	(250,861)	[1]	8,107
Financing activities
Deposit with Newborn	0	[1]	(287,500)
Proceeds from Newborn Escrow Account	0	[1]	58,471,961
Redemption of Newborn shares	0	[1]	(18,630)
Issuance costs related to reverse recapitalization and PIPE offering	0	[1]	(3,704,921)
Proceeds from PIPE offering	0	[1]	14,250,000
Repayment of Newborn sponsor loans	0	[1]	(487,500)
Repurchase of common stock from EDF	0	[1]	(6,000,000)
Newborn cash acquired	0	[1]	50,206
Payment of finance lease Obligations	(2,073)	[1]	0
Net cash (used) provided in financing activities	(2,073)	[1]	62,273,616
Effect of exchange rate on cash	146,949	[1]	119,541
Net increase (decrease) in cash and restricted cash	(8,555,874)	[1]	59,767,413
Cash and restricted cash at beginning of year	32,740,520	[1]	2,275,895	2,275,895
Cash and restricted cash at end of period	24,184,646	[1]	62,043,308	$ 32,740,520	[1]	$ 2,275,895
Supplemental Disclosure of Noncash Financing Activity
Conversion of preferred stock to common stock	0		1,679
Conversion of debenture and accrued interest to common shares	0		3,999,435
Conversion of shares due to reverse recapitalization	0		3,383
Issuance of common stock for merger success fee	0		2,085,299
Non-cash merger transaction costs	0		2,085,299
Accrued transaction costs related to reverse recapitalization	0		189,434
Issuance of private warrants	0		1,253,228
Transfer of Inventory to property and equipment	$ 87,095		$ 0
[1](1) See Note 2.[2]Note 2.[3]See Note 2[4]See Note 2.

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Description of Business Nuvve Holding Corp., a Delaware corporation headquartered in San Diego, California (the “Company” or “Nuvve”), was founded on November 10, 2020 under the laws of the state of Delaware. On March 19, 2021, the Company (at the time known as NB Merger Corp.) acquired the outstanding shares of Nuvve Corporation (“Nuvve Corp.”), and the Company changed its name to Nuvve Holding Corp. Structure of the Company Nuvve has two wholly owned subsidiaries, Nuvve Corp. and Nuvve Co (Nuvve Japan). Nuvve Corp. has three wholly owned subsidiaries: (1) Nuvve Denmark ApS, (“Nuvve Denmark”), a company registered in Denmark, (2) Nuvve SaS, a company registered in France, and (3) Nuvve LTD, a company registered in United Kingdom. In March 2020, following the establishment of its investment in Dreev in 2019 (Note 6), the Company ceased operations of its subsidiary, Nuvve SaS in France. The two employees of Nuvve SaS resigned from the Company in March 2020 and were concurrently hired by Dreev. Financial results for Nuvve SaS are included in the Company’s financial results through the cessation of operations. On August 4, 2021, the Company formed Levo Mobility LLC, a Delaware limited liability company ("Levo"), with Stonepeak Rocket Holdings LP, a Delaware limited partnership (Stonepeak"), and Evolve Transition Infrastructure LP, a Delaware limited partnership ("Evolve"). Levo is a consolidated a entity of the Company. Please see Note 2 for the principles of consolidation. Levo is a sustainable infrastructure company focused on rapidly advancing the electrification of transportation by funding V2G-enabled EV fleet deployments. Levo utilizes Nuvve’s V2G technology and committed capital from Stonepeak and Evolve to offer Fleet-as-a-Service for school buses, last-mile delivery, ride hailing and ride sharing, municipal services, and more to eliminate the primary barriers to EV fleet adoption including large upfront capital investments and lack of expertise in securing and managing EVs and associated charging infrastructure. Levo's turnkey solution simplifies and streamlines electrification, can lower the total cost of EV operation for fleet owners, and support the grid when the EVs are not in use. For a fixed monthly payment with no upfront cost, Levo will provide the EVs, such as electric school buses, charging infrastructure powered by Nuvve’s V2G platform, EV and charging station maintenance, energy management, and technical advice. Levo will initially focus on electrifying school buses, providing associated charging infrastructure, and delivering V2G services to enable safer and healthier transportation for children while supporting carbon dioxide emission reduction, renewable energy integration, and improved grid resiliency.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies For a detailed discussion about the Company’s significant accounting policies, see Note 2, “ Summary of Significant Accounting Policies ,” in the Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”). During the three months ended March 31, 2022, there were no significant updates made to the Company’s significant accounting policies. Basis of Presentation The accompanying unaudited (i) condensed consolidated balance sheet as of December 31, 2021, which has been derived from audited financial statements, and (ii) the unaudited interim condensed financial statements have been prepared in accordance pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Therefore, it is suggested that these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes in the 2021 Form 10-K, filed with the Securities and Exchange Commission ("SEC") on March 31, 2022. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, comprehensive loss, cash flows, and stockholders’ equity for the interim periods, but are not necessarily indicative of the results to be anticipated for the full year 2022 or any future period. In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the that the consolidated financial statements are issued. Since inception, the Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $97.6 million as of March 31, 2022. Nuvve incurred operating losses of approximately $9.5 million for the quarter ended March 31, 2022, and $27.2 million and $4.7 million for the years ended December 31, 2021, and 2020, respectively. As of March 31, 2022, Nuvve had a cash balance, working capital, and stockholders’ equity of $23.7 million, $28.8 million and $23.5 million, respectively. The Company continues to expect to generate operating losses and negative cash flows and may need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful expanded commercialization of the Company's GIVe platform and the achievement of a level of revenues adequate to support its cost structure. The Company expects its cash and cash equivalents as of May 12, 2022 will be sufficient to fund current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements. Management's expectations with respect to its ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. Actual results could be different from management's estimates and should actual results be less favorable than these estimates management would ultimately need to take corrective steps to improve future operating results and its financial condition. Restatement of Previously Issued Financial Statements Subsequent to the issuance of the company’s condensed consolidated financial statements as of March 2022 and 2021, errors were identified relating to the following: The associated income tax expense or benefit and related deferred tax assets or liabilities have been reflected, including the impact of valuation allowance. (1) Unvested warrants issued to Stonepeak and Evolve in May 2021, as described in Note 11, should be accounted for as a single unit of account as opposed to multiple units of account. As a result, these unvested warrants, which were previously recorded in equity, have been reclassified to liabilities on the consolidated balance sheet. As a single unit of account, the unvested warrants’ settlement value is impacted by the amount of capital expenditures associated with Levo’s customer contracts, which caused the unvested warrants to not be indexed to the Company's equity. The unvested warrant liability is adjusted to its estimated fair value at each reporting date. (2) As part of the fair value of warrants and stock option (“Instruments”) granted to Stonepeak and Evolve in May 2021, in conjunction with the formation of Levo, the Company inaccurately capitalized the costs incurred to deferred financing costs, and should have expensed such costs. The Company determined that there was not sufficient basis to record deferred financing costs associated with Stonepeak and Evolve’s plans to contribute capital to the Levo venture. As a result, the estimated fair value of the Instruments that were previously recorded as a capitalized asset are corrected to recognize an expense upon issuance of the Instruments during the second quarter of 2021. The expense is non-cash and does not impact the existing conditional capital commitment the Company has from Stonepeak and Evolve or the pursuit of customer deployments funded by this conditional capital commitment. The associated income tax expense or benefit and related deferred tax assets or liabilities have been reflected, including the impact of valuation allowance. The following tables summarize the effect of the aforementioned adjustments on the Company's Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021, and the Company's Condensed Consolidated Statement of Operations, and Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2022: Condensed Consolidated Balance Sheets March 31, 2022 March 31, 2022 Assets As Previously Reported Adjustment As Restated Deferred financing costs $ 43,562,847 $ (43,562,847) $ — Total Assets $ 86,520,460 $ (43,562,847) $ 42,957,613 Current Liabilities Warrants liability $ 458,476 $ 4,333,999 $ 4,792,475 Total Liabilities $ 12,062,586 $ 4,333,999 $ 16,396,585 Mezzanine equity Redeemable non-controlling interests, preferred shares, zero par value, 1,000,000 shares authorized, 3,138 shares issue and outstanding at March 31, 2022 and December 31, 2021; aggregate liquidation preference of $3,264,775 at March 31, 2022 $ 3,046,892 $ 16,472 $ 3,063,365 Stockholders’ (Deficit) Equity Additional paid-in capital $ 128,594,145 $ (4,801,897) $ 123,792,248 Accumulated deficit $ (56,385,798) $ (41,182,393) $ (97,568,191) Nuvve Stockholders’ Equity (Deficit) $ 72,310,000 $ (45,984,290) $ 26,325,710 Non-controlling interests $ (899,018) $ (1,929,029) $ (2,828,047) Total Stockholders’ Equity (Deficit) $ 71,410,982 $ (47,913,319) $ 23,497,663 Total Liabilities, Mezzanine equity and Stockholders’ Equity $ 86,520,460 $ (43,562,847) $ 42,957,613 Three Months Ended March 31, Three Months Ended March 31, 2022 2022 Condensed Consolidated Statement of Operations As Previously Reported Adjustment As Restated Change in fair value of warrants liability $ 433,000 $ 4,343,000 $ 4,776,000 Total other (expense) income, net $ 458,143 $ 4,343,000 $ 4,801,143 Loss before taxes $ (9,074,261) $ 4,343,000 $ (4,731,261) Net loss $ (9,074,261) $ 4,343,000 $ (4,731,261) Net loss attributable to Nuvve Holding Corp. $ (8,973,328) $ 4,343,000 $ (4,630,328) Net loss attributable to Nuvve common stockholders $ (9,198,809) $ 4,343,000 $ (4,855,809) Net loss per share attributable to Nuvve common stockholders, basic and diluted $ (0.49) $ 0.23 $ (0.26) Three Months Ended March 30, Three Months Ended March 30, 2022 2022 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS As Previously Reported Adjustment As Restated Net loss $ (9,074,261) 4,343,000 $ (4,731,261) Comprehensive loss attributable to Nuvve common stockholders $ (8,761,531) 4,343,000 $ (4,418,531) CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY As Previously Reported Adjustment As Restated Net Loss $ (9,074,261) $ 4,343,000 $ (4,731,261) Balance March 31, 2022 $ 71,410,982 $ (47,913,319) $ 23,497,663 Three Months Ended March 31, Three Months Ended March 31, 2022 2022 Condensed Consolidated Statement of Cash Flows As Previously Reported Adjustment As Restated Operating activities Net loss $ (9,074,261.00) $ 4,343,000.00 $ (4,731,261.00) Adjustments to reconcile to net loss to net cash used in operating activities Change in fair value of warrants liability $ (433,000.00) $ (4,343,000.00) $ (4,776,000.00) Net cash used in operating activities $ (8,449,889.00) $ — $ (8,449,889.00) Principles of Consolidation The condensed consolidated financial statements include the accounts and operations of the Company, its wholly owned subsidiaries and its consolidated variable interest entity. All intercompany accounts and transactions have been eliminated upon consolidation. Variable Interest Entities Pursuant to the consolidation guidance, the Company first evaluates whether it holds a variable interest in an entity in which it has a financial relationship and, if so, whether or not that entity is a variable interest entity ("VIE"). A VIE is an entity with insufficient equity at risk for the entity to finance its activities without additional subordinated financial support or in which equity investors lack the characteristics of a controlling financial interest. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company concludes that it is the primary beneficiary and consolidates the VIE if the Company has both (i) the power to direct the activities of the VIE that most significantly influence the VIE's economic performance, and (ii) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. The Company formed Levo with Stonepeak and Evolve, in which the Company owns 51% of Levo's common units. The Company has determined that Levo is a VIE in which the Company is the primary beneficiary. Accordingly, the Company consolidates Levo and records a non-controlling interest for the share of the entity owned by Stonepeak and Evolve. Assets and Liabilities of Consolidated VIEs The Company's condensed consolidated financial statements include the assets, liabilities and results of operations of VIEs for which the Company is the primary beneficiary. The other equity holders’ interests are reflected in "Net loss attributable to non-controlling interests" in the condensed consolidated statements of operations and "Non-controlling interests" in the condensed consolidated balance sheets. See Note 18 for details of non-controlling interests. The Company began consolidating the assets, liabilities and results of operations of Levo during the quarter ended March 31, 2022. The creditors of the consolidated VIE do not have recourse to the Company other than to the assets of the consolidated VIEs. The following table summarizes the carrying amounts of Levo assets and liabilities included in the Company’s condensed consolidated balance sheets at March 31, 2022: March 31, 2022 Assets Cash $ 28,257 Total Assets $ 28,257 Liabilities and Mezzanine Equity Accrued expenses $ 236,775 Derivative liability - non-controlling redeemable preferred shares 458,476 Total Liabilities $ 695,251 Redeemable Non-Controlling Interest - Mezzanine Equity Redeemable non-controlling interest represents the shares of the preferred stock issued by Levo to Stonepeak and Evolve (the "preferred shareholders") who own 49% of Levo common units. The preferred stock is not mandatorily redeemable or currently redeemable, but it could be redeemable with the passage of time at the election of Levo, the preferred shareholders or a trigger event as defined in the preferred stock agreement. As a result of the contingent put right available to the preferred shareholders, the redeemable non-controlling interests in Levo are classified outside of permanent equity in the Company’s unaudited condensed consolidated balance sheets as mezzanine equity. The initial carrying value of the redeemable non-controlling interest is reported at the initial proceeds received on issuance date, reduced by the fair value of embedded derivatives resulting in an adjusted initial carrying value. The adjusted initial carrying value is further adjusted for the accretion of the difference with the redemption price value using the effective interest method. The accretion amount is a deemed dividend recorded against retained earnings or, in its absence, to additional-paid-in-capital. The carrying amount of the redeemable non-controlling interest is measured at the higher of the carrying amount adjusted each reporting period for income (or loss) attributable to the non-controlling interest, or the carrying amount adjusted each reporting period by the accretion amount. See Note 18 for details. Non-controlling interests The Company presents non-controlling interests as a component of equity on its condensed consolidated balance sheets and reports the portion of its earnings or loss for non-controlling interest as net earnings or loss attributable to non-controlling interests in the condensed consolidated statements of operations. Emerging Growth Company Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) permits emerging growth companies (“EGC”) to delay complying with new or revised financial accounting standards that do not yet apply to private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act). The Company qualifies as an EGC. The JOBS Act provides that an EGC can elect to opt-out of the extended transition period and comply with the requirements that apply to non-EGCs, but any such election to opt-out is irrevocable. The Company has elected not to opt-out of such an extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an EGC, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This different adoption timing may make a comparison of the Company’s financial statements with another public company which is neither an EGC nor an EGC that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. COVID-19 The novel coronavirus (COVID-19) which was declared a pandemic in March 2020, and the related restrictive measures such as travel restrictions, quarantines, and shutdowns, has negatively impacted the global economy. As national and local governments in different countries ease COVID-19 restrictions, and vaccines are distributed and rolled out successfully, we continue to see improved economic trends. However, COVID-19 and actions taken to mitigate its spread have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. The Company continues to monitor the situation closely but, at this time, is unable to predict the cumulative impact, both in terms of severity and duration, that the coronavirus pandemic has and will have on its business, operating results, cash flows and financial condition, and it could be material if the current circumstances continue to exist for a prolonged period of time. In addition to any direct impact on Nuvve’s business, it is reasonably possible that the estimates made by management in preparing Nuvve’s financial statements have been, or will be, materially and adversely impacted in the near term as a result of the on-going COVID-19 conditions. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include the impairment of intangible assets, the net realizable value of inventory, the fair value of share-based payments, the fair value of notes payable conversion options, revenue recognition, the fair value of warrants, and the recognition and disclosure of contingent liabilities. Management evaluates its estimates on an ongoing basis. Actual results could materially vary from those estimates. Cash and Restricted Cash The Company maintains cash balances that can, at times, exceed amounts insured by the Federal Deposit Insurance Corporation, which is up to $250,000. The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area. Concentrations of Credit Risk At March 31, 2022 and December 31, 2021, the financial instruments which potentially expose the Company to concentration of credit risk consist of cash in financial institutions (in excess of federally insured limits) and trade receivables. The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable, as follows: For the three months ended March 31, 2022 and 2021, one customer accounted for 72.8%, and two customers in aggregate accounted for 49.9% of revenue, respectively. During the three months ended March 31, 2022 and 2021 , the Company's top five customers accounted for approximately 87.5% and 71.4%, respectively, o f the Company’s total revenue. At March 31, 2022 , two customers in aggregate accounted for 35.7% of accounts receivable. At December 31, 2021 , two customers in aggregate accounted for 32.2% of accounts receivable. Approximately 58.7% and 56.0% of the Company’s trade accounts receivable balance was with five customers at March 31, 2022 and December 31, 2021 , respectively. The Company estimates its maximum credit risk for accounts receivable at the amount recorded on the balance sheet. The trade accounts receivables are generally short-term and all probable bad debt losses have been appropriately considered in establishing the allowance for doubtful accounts. Recently adopted accounting pronouncements None. Recently issued accounting pronouncements not yet adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires, among other things, the use of a new current expected credit loss ("CECL") model in determining the allowances for doubtful accounts with respect to accounts receivable, accrued straight-line rents receivable, and notes receivable. The CECL model requires that an entity estimate its lifetime expected credit loss with respect to these receivables and record allowances that, when deducted from the balance of the receivables, represent the net amounts expected to be collected. Entities will also be required to disclose information about how the entity developed the allowances, including changes in the factors that influenced its estimate of expected credit losses and the reasons for those changes. This update is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The disclosures below discuss the Company’s material revenue contracts. The following table provides information regarding disaggregated revenue based on revenue by service lines for the three months ended March 31: Three Months Ended March 31, 2022 2021 Revenue recognized over time: Services $ 194,650 $ 167,245 Grants 117,249 487,129 Products 2,059,134 144,658 Total revenue $ 2,371,033 $ 799,032 The aggregate amount of revenue for the Company’s existing contracts with customers as of March 31, 2022 expected to be recognized in the future, and classified as deferred revenue on the condensed consolidated Balance Sheet, for years ended December 31, is as follows (this disclosure does not include revenue related to contracts whose original expected duration is one year or less): 2022 (remaining nine months) $ 540,331 Thereafter 150,537 Total $ 690,868 Segment Reporting The Company operates in a single business segment, which is the EV V2G Charging segment. The following table summarizes the Company’s revenues for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 Revenues: United States $ 2,227,734 $ 591,831 United Kingdom 37,390 141,286 Denmark 105,909 65,915 $ 2,371,033 $ 799,032 The following table summarizes the Company’s long-lived assets in different geographic locations as of March 31, 2022 and December 31, 2021: March 31, December 31, Long-lived assets: United States $ 1,948,891 $ 1,811,607 Denmark 23,550 25,664 $ 1,972,441 $ 1,837,271

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following are the liabilities measured at fair value on the condensed consolidated balance sheet at March 31, 2022 using quoted price in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3): Level 1: Level 2: Level 3: Total at March 31, Total Gains (Losses) For The Three Months Ended March 31, 2022 Recurring fair value measurements Private warrants $ — $ — $ 433,000 $ 433,000 $ 433,000 Stonepeak and Evolve unvested warrants $ — $ — $ 4,334,000 $ 4,334,000 $ 4,343,000 Derivative liability - non-controlling redeemable preferred shares $ — $ — $ 458,476 $ 458,476 $ 53,472 Total recurring fair value measurements $ — $ — $ 5,225,476 $ 5,225,476 $ 4,829,472 The following is a reconciliation of the opening and closing balances for the liabilities related to the warrants (Note 11) and derivative liability - non-controlling redeemable preferred shares measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2022: Private Warrants Stonepeak and Evolve unvested warrants Non-controlling redeemable preferred shares - derivative liability (Restated) (1) Balance at December 31, 2021 $ 866,000 $ 8,677,000 $ 511,948 Total (gains) losses for period included in earnings (433,000) (4,343,000) (53,472) Balance at March 31, 2022 $ 433,000 $ 4,334,000 $ 458,476 The fair value of the level 3 Private Warrants was estimated at March 31, 2022 using the Black-Scholes model which used the following inputs: term of 3.97 years, risk free rate of 2.4%, no dividends, volatility of 64.0%, and strike price of $11.50. The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve unvested warrants: Series C Unvested Warrants Series D Unvested Warrants Series E Unvested Warrants Series F Unvested Warrants Fair value (in millions) $1.7 $1.2 $0.8 $0.6 Valuation methodology Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Term (years) 9.10 9.10 9.10 9.10 Risk free rate 2.3% 2.3% 2.3% 2.3% Exercise price $15.0 $20.0 $30.0 $40.0 Volatility 56.0% 56.0% 56.0% 56.0% Capital expenditure forecast (in millions) $125.0 $250.0 $375.0 $500.0 Probability of warrants vesting 90.8% 76.0% 63.8% 54.4% The fair value of the level 3 derivative liability - non-controlling redeemable preferred shares are estimated at March 31, 2022 using the M onte Carlo Simulation model which used the following inputs: terms range from 3.0 years to 7.0 years, risk free rate of 2.4%, no dividends, volatility of 56.0% and probability of redemptions triggered of 75.0%. There were no transfers between Level 1 and Level 2 of the fair value hierarchy in 2022 and 2021. Cash, accounts receivable, accounts payable, and accrued expenses are generally carried on the cost basis, which management believes approximates fair value due to the short-term maturity of these instruments.

Derivative Liability - Non-Cont

Derivative Liability - Non-Controlling Redeemable Preferred Stock	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability - Non-Controlling Redeemable Preferred Stock	Derivative Liability - Non-Controlling Redeemable Preferred Stock The Company has determined that the redemption features embedded in the non-controlling redeemable preferred stock is required to be accounted for separately from the redeemable preferred stock as a derivative liability. Separation of the redemption features as a derivative liability is required because its economic characteristics and risks are considered more akin to a debt instrument, and therefore, not considered to be clearly and closely related to the economic characteristics of the redeemable preferred stock. The economic characteristics of the redemption features are considered more akin to an debt instrument because the minimum redemption value could be greater than the face amount, the redemption features are contingently exercisable, and the shares carry a fixed mandatory dividend. Accordingly, the Company has recorded an embedded derivative liability representing the estimated fair value of the right of the holders to exercise their redemption option upon the occurrence of a redemption event. The embedded derivative liability is adjusted to reflect fair value at each period end with changes in fair value recorded in the “Change in fair value of derivative liability” financial statement line item of the company’s consolidated statements of operations. For additional information on the non-controlling redeemable preferred stock, see Note 18 . The following table display the fair value of derivatives by balance sheet line item at March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 Other long term liabilities: Derivative liability - non-controlling redeemable preferred shares $ 458,476 $ 511,948

Investment in Dreev

Investment in Dreev	3 Months Ended
	Mar. 31, 2022
Investments [Abstract]
Investment in Dreev	Investment in Dreev The Company accounts for its 13% equity ownership in Dreev under the cost method. The Company has a consulting services agreement with Dreev related to software development and operations. The consulting services were zero fo r each of the three months ended March 31, 2022 and 2021. The consulting services are being provided to Dreev at the Company’s cost and is recognized, net of consulting costs, as other income, net in the condensed consolidated statements of operations.

Account Receivables, Net

Account Receivables, Net	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Account Receivables, Net	Account Receivables, Net The following tables summarizes the Company's accounts receivable on the consolidated balance sheets at March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 Trade receivables $ 1,494,322 $ 1,949,896 Less: allowance for doubtful accounts (63,188) (63,188) Accounts receivable, net $ 1,431,134 $ 1,886,708 Allowance for doubtful accounts: Balance December 31, 2021 $ (63,188) Provision — Write-off — Recoveries — Balance March 31, 2022 $ (63,188)

Inventories

Inventories	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories The following table summarizes the Company’s inventories balance by category: March 31, 2022 December 31, 2021 DC Chargers $ 7,431,300 $ 7,687,598 AC Chargers 204,687 232,920 Vehicles - School Buses (1) 1,620,000 3,180,000 Others 72,219 17,670 Total $ 9,328,206 $ 11,118,188 __________________ (1) As of March 31, 2022, the Company has taken delivery of ten school buses it has committed to purchase from the manufacturer within one year from the purchase order date of May 26, 2021. During the first quarter ended March 31, 2022, five school buses were sold.

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment The following table summarizes the Company’s property, plant and equipment balance at March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 Computers & Servers $ 113,490 $ 105,499 Vehicles 168,862 168,862 Office furniture and equipment 317,546 161,771 Others 93,146 6,050 Total 693,044 442,182 Less: Accumulated Depreciation (120,545) (85,988) Property, plant and equipment, net $ 572,499 $ 356,194 March 31, 2022 March 31, 2021 Depreciation expense $ 25,975 $ 6,508

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets At both March 31, 2022 and December 31, 2021, the Company had recorded a gross intangible asset balance of $2,091,556, which is related to patent and intangible property rights acquired. Amortization expense of intangible assets was $34,860 each for the three months ended March 31, 2022 and 2021. Accumulated amortization totaled $645,340 and $610,480 at March 31, 2022 and December 31, 2021, respectively. The net amount of intangible assets of $1,446,218 at March 31, 2022, will be amortized over the weighted average remaining life of 10.6 years . Total estimated future amortization expense is as follows: 2022 (remaining nine months) $ 104,577 2023 139,437 2024 139,437 2025 139,437 2026 139,437 Thereafter 783,893 $ 1,446,218

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	Stockholders’ Equity As of March 31, 2022, the Company has authorized two classes of stock, Common Stock, and Preferred Stock. The total number of shares of all classes of capital stock which the Company has authority to issue is 101,000,000, of which 100,000,000 authorized shares are Common Stock with a par value of $0.0001 per share (“Common Stock”), and 1,000,000 authorized shares are Preferred Stock of the par value of $0.0001 per share (“Preferred Stock”). Please see Note 12, “ Stockholders' Equity ,” in the Notes to Consolidated Financial Statements included in the Company’s 2021 Form 10-K for a detailed discussion of the Company’s stockholders' equity. Additionally, see Note 19, “Levo Mobility LLC Entity,” in the Notes to Consolidated Financial Statements included in the Company’s 2021 Form 10-K for a detailed discussion of the Company’s Stonepeak and Evolve Warrants and Securities Purchase agreement, and Levo definitive agreements. Warrants - Stonepeak and Evolve On May 17, 2021, in connection with the signing of a letter of agreement, as reference above, relating to the formation of a venture, Levo Mobility LLC (the "Letter Agreement"), the Company issued to Stonepeak and Evolve a ten years warrants to purchase common stock (allocated 90% to Stonepeak and 10% to Evolve). See below for details. The grant-date fair value of the warrants issued to Stonepeak and Evolve were; series B $12.8 million, series C $5.6 million, series D $4.8 million, series E $3.8 million and series F $3.2 million. The fair values of the vested warrants are recorded in the consolidated balance sheets in additional-paid-in capital in stockholders' equity as the vested warrants are indexed to the Company’s common stock and meet the conditions for equity classification. The unvested warrants are recorded as a liability in the consolidated balance sheet at fair value, with changes in fair value recorded in the consolidated statement of operations, as the unvested warrants are deemed not to be indexed to the Company’s common stock. See Note 4 for details of changes in fair value of the unvested warrants recorded in the consolidated statement of operations. In connection with the signing of the Letter Agreement, the Company issued to Stonepeak and Evolve the following ten years warrants to purchase common stock (allocated 90% to Stonepeak and 10% to Evolve): • Series B warrants to purchase 2,000,000 shares of the Company’s common stock, at an exercise price of $10.00 per share, which are fully vested upon issuance, • Series C warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $15.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $125 million in aggregate capital expenditures, • Series D warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $20.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $250 million in aggregate capital expenditures, • Series E warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $30.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $375 million in aggregate capital expenditures, and • Series F warrants to purchase 1,000,000 shares of the Company’s common stock, at an exercise price of $40.00 per share, which are vested as to 50% of the shares upon issuance and vest as to the remaining 50% when Levo has entered into contracts with third parties for $500 million in aggregate capital expenditures. The warrants may be exercised at any time on or after the date that is 180 days after the applicable vesting date. Warrants - Public and Private In connection with its initial public offering on February 19, 2020, Newborn sold 5,750,000 units, which included one warrant to purchase Newborn’s common stock (the “Public Warrants”). Also, on February 19, 2020, NeoGenesis Holding Co., Ltd., Newborn’s sponsor (“the Sponsor”), purchased an aggregate of 272,500 private units, each of which included one warrant (the “Private Warrants”), which have the same terms as the Public Warrants. Upon completion of the merger between Nuvve and Newborn, the Public Warrants and Private Warrants were automatically converted to warrants to purchase Common Stock of the Company. The terms of the Private Warrants are identical to the Public Warrants as described above, except that the Private Warrants are not redeemable so long as they are held by the Sponsor or its permitted transferees. Concurrently with the execution of the Merger Agreement on November 11, 2020, Newborn entered into subscription agreements with certain accredited investors pursuant to which the investors agreed to purchase 1,425,000 of Newborn’s common stock, at a purchase price of $10.00 per share, for an aggregate purchase price of $14,250,000 (the PIPE). Upon closing of the PIPE immediately prior to the closing of the Business Combination, the PIPE investors also received 1.9 PIPE Warrants to purchase the Company’s Common Stock for each share of Common Stock purchased. The PIPE Warrants are each exercisable for one-half of a common share at $11.50 per share and have the same terms as described above for the Public Warrants. The PIPE investors received demand and piggyback registration rights in connection with the securities issued to them. The following table is a summary of the number of shares of the Company’s Common Stock issuable upon exercise of warrants outstanding at March 31, 2022 (there were no warrants outstanding at December 31, 2021): Number of Number of Exercise Expiration Public Warrants 2,875,000 2,875,000 $11.50 March 19, 2026 Private Warrants 136,250 136,250 $11.50 March 19, 2026 PIPE Warrants 1,353,750 1,353,750 $11.50 March 19, 2026 Stonepeak/Evolve Warrants - series B 2,000,000 2,000,000 $10.00 May 17, 2031 Stonepeak/Evolve Warrants - series C 1,000,000 500,000 $15.00 May 17, 2031 Stonepeak/Evolve Warrants - series D 1,000,000 500,000 $20.00 May 17, 2031 Stonepeak/Evolve Warrants - series E 1,000,000 500,000 $30.00 May 17, 2031 Stonepeak/Evolve Warrants - series F 1,000,000 500,000 $40.00 May 17, 2031 10,365,000 8,365,000 Because the Private Warrants have dissimilar terms with respect to the Company’s redemption rights depending on the holder of the Private Warrants, the Company determined that the Private Warrants are required to be carried as a liability in the condensed consolidated balance sheet at fair value, with changes in fair value recorded in the condensed consolidated statement of operations. The Private Warrants are reflected as a liability in the condensed consolidated balance sheet as of March 31, 2022 in the amount of $433,000 and the change in the fair value of the Private Warrant for the three months ended March 31, 2022 of is reflected as a gain of $433,000, in the condensed consolidated statement of operations. Unit Purchase Option On February 19, 2020, Newborn sold to the underwriters of its initial public offering for $100, a unit purchase option ("UPO") to purchase up to a total of 316,250 units at $11.50 per unit (or an aggregate exercise price of $3,636,875) commencing on the date of Newborn's initial business combination, March 19, 2021, and expiring February 13, 2025. Each unit issuable upon exercise of the UPO consists of one and one-tenth of a share of the Company's common stock and one warrant to purchase one share of the Company's common stock at the exercise price of $11.50 per share. The warrant has the same terms as the Public Warrant. In no event will the Company be required to net cash settle the exercise of the UPO or the warrants underlying the UPO. The holders of the unit purchase option have demand and "piggy back" registration rights for periods of five ASC 815-40, Derivatives and Hedging-Contracts in an Entity’s Own Equity, as the UPO is indexed to the Company’s common stock and meets the conditions for equity classification. Securities Purchase Agreement On May 17, 2021, in connection with the signing of a letter of agreement relating to the formation of a venture, Levo Mobility LLC, the Company entered into a Securities Purchase Agreement with Stonepeak and Evolve which provide them from time to time between November 13, 2021 and November 17, 2028, in their sole discretion, to purchase up to an aggregate of $250 million in shares of the Company’s common stock at a purchase price of $50.00 per share (allocated 90% to Stonepeak and 10% to Evolve). See below f or details. The grant-date fair value of the Securities Purchase Agreement to purchase shares of the Company’s common stock was $12.6 million, and is recorded in the condensed consolidated balance sheet as equity in additional-paid-in capital as it is indexed to the Company’s common stock and meets the conditions for equity classification, and deferred financing costs. The carrying amount of the deferred financing costs is reduced as the commitment amount is funded, and the amount is charged to additional-paid-in capital. In connection with the signing of the Letter Agreement, as reference above, the Company also entered into a Securities Purchase Agreement (the “SPA”) and a Registration Rights Agreement (the “RRA”) with Stonepeak and Evolve. • Under the SPA, from time to time between November 13, 2021 and November 17, 2028, Stonepeak and Evolve may elect, in their sole discretion, to purchase up to an aggregate of $250 million in shares of the Company’s common stock at a purchase price of $50.00 per share (allocated 90% to Stonepeak and 10% to Evolve). The SPA includes customary representations and warranties and closing conditions and customary indemnification provisions. In addition, Stonepeak and Evolve may elect to purchase shares under the SPA on a cashless basis in the event of a change of control of the Company.

Stock Option Plan

Stock Option Plan	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock Option Plan	Stock Option Plan In 2010, the Company adopted the 2010 Equity Incentive Plan (the “2010 Plan”), which provides for the grant of restricted stock awards, stock options, and other share-based awards to employees, consultants, and directors. In November 2020, the Company’s Board of Directors extended the term of the 2010 Plan to July 1, 2021. In 2021, the Company adopted the 2020 Equity Incentive Plan (the “2020 Plan”), which provides for the grant of restricted stock awards, incentive and non-statutory stock options, and other share-based awards to employees, consultants, and directors. As of March 31, 2022, there is an aggregate of 3,300,000 common shares reserved for issuance under the 2020 Plan. All options granted to date have a ten years contractual life and vesting terms of four years. In general, vested options expire if not exercised at termination of service. As of March 31, 2022, a total of 1,321,374 shares of common stock remained available for future issuance under the 2020 Plan. Stock-based compensation expense for the three months ended March 31 are as follows Three Months Ended March 31, 2022 2021 Options $ 822,106 $ 262,105 Restricted stock 613,839 — Total $ 1,435,945 $ 262,105 The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options. Fair value is estimated at the date of grant for employee and nonemployee options. The following assumptions were used in the Black-Scholes model to calculate the fair value of stock options granted for the three months ended March 31, 2022 for the 2010 Plan and the 2020 Plan. 2010 Plan 2020 Plan Expected life of options (in years) (1) 6.1 6.1 Dividend yield (2) 0 % 0 % Risk-free interest rate (3) 2.00 % 2.00 % Volatility (4) 54.4 % 54.4 % __________________ (1) The expected life of options is the average of the contractual term of the options and the vesting period. (2) No cash dividends have been declared on the Company’s common stock since the Company’s inception, and the Company currently does not anticipate declaring or paying cash dividends over the expected life of the options. (3) The risk-free interest rate is based on the yields on U.S. Treasury debt securities with maturities approximating the estimated life of the options. (4) Volatility is estimated by management. As the Company has been a private company for most of its existence, there is not enough historical volatility data related to the Company’s Common stock as a public entity. Therefore, this estimate is based on the average volatility of certain public company peers within the Company’s industry. The following is a summary of the stock option activity under the 2010 Plan, as converted to the Company’s shares due to Reverse Recapitalization, for the three months ended March 31, 2022: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2021 1,035,035 3.21 5.90 5,688,201 Granted — — — — Exercised — — — — Forfeited — — — — Expired/Cancelled (5,310) 1.37 — — Outstanding - March 31, 2022 1,029,725 3.22 5.69 5,649,500 Options Exercisable at March 31, 2022 857,024 2.43 5.14 5,344,262 Option Vested at March 31, 2022 857,024 2.43 5.14 5,344,262 The weighted-average grant-date fair value of options granted during the three months ended March 31, 2022 was zero. The following is a summary of the stock option activity under the 2020 Plan for the three months ended March 31, 2022: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2021 1,602,850 13.18 9.27 46,920 Granted 106,000 6.77 9.86 — Exercised — — — — Forfeited — — — — Expired/Cancelled — — — — Outstanding - March 31, 2022 1,708,850 12.78 9.07 252,560 Options Exercisable at March 31, 2022 330,062 13.70 — — Option Vested at March 31, 2022 330,062 13.70 — — The weighted-average grant-date fair value of options granted during the three months ended March 31, 2022 was $3.58. During the year ended December 31, 2021 1,640,000 options were modified to lower the exercise price by $0.60 per share, which will result in $246,000 of incremental compensation cost to be recognized over the remaining vesting period. The amount of additional compensation expense for the three months ended March 31, 2022 and 2021, were $19,699 and zero, respectively . Other Information: Three Months Ended 2022 2021 Amount received from option exercised $ — $ — March 31, 2022 Weighted average remaining recognition period Total unrecognized options compensation costs $ 9,987,990 2.98 No amounts relating to the Plan have been capitalized. Compensation cost is recognized over the requisite service period based on the fair value of the options. A summary of the status of the Company’s nonvested restricted stock units as of December 31, 2021, and changes during the three months ended March 31, 2022, is presented below: Shares Weighted- Nonvested at December 31, 2021 353,817 11.00 Granted 27,478 10.15 Vested/Release (30,370) 13.79 Cancelled/Forfeited — — Nonvested and Outstanding at March 31, 2022 350,925 10.70 As of March 31, 2022, there was $2,200,843 of total unrecognized compensation cost related to nonvested restricted stock. The Company expects to recognize this compensation cost over a remaining weighted-average period of approximately 1.4 years.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Three Months Ended March 31, 2022 2021 Income tax (benefit) expense $ — $ — Effective tax rate 0.0 % (0.1) % The effective tax rate used for interim periods is the estimated annual effective tax rate, based on current estimate of full year results, except that taxes related to specific events, if any, are recorded in the interim period in which they occur. The effective tax rate differed from the U.S. federal statutory tax rate primarily due to operating losses that receive no tax benefit as a result of a valuation allowance recorded for such losses. The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes (“ASC 740”). Under the provisions of ASC 740, management is required to evaluate whether a valuation allowance should be established against its deferred tax assets. The Company currently has a full valuation allowance against its deferred tax assets. As of each reporting date, the Company’s management considers new evidence, both positive and negative, that could impact management’s view with regard to future realization of deferred tax assets. For the three months ended March 31, 2022, there was no material change from the year ended December 31, 2021 in the amount of the Company’s deferred tax assets that are not considered to be more likely than not to be realized in future years.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders The following table sets forth the calculation of basic and diluted net loss per share attributable to common stockholders during the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (Restated) (1) Net loss attributable to Nuvve common stockholders $ (4,855,809) $ (5,361,720) Weighted-average shares used to compute net loss per share attributable to Nuvve common stockholders, basic and diluted 18,864,374 10,408,080 Net Loss per share attributable to Nuvve common stockholders, basic and diluted $ (0.26) $ (0.52) (1) As described in Note 2 to these condensed Consolidated Financial Statements, the Company has restated the condensed Consolidated Financial Statements. The following outstanding shares of common stock equivalents were excluded from the calculation of the diluted net loss per share attributable to Nuvve common stockholders because their effect would have been anti-dilutive: Three Months Ended March 31, 2022 2021 Stock options issued and outstanding 2,773,734 1,415,355 Nonvested restricted stock issued and outstanding 880,892 7,873 Public warrants 2,875,000 2,875,000 Private warrants 136,250 136,250 PIPE warrants 1,353,750 1,353,750 Stonepeak and Evolve warrants 6,000,000 — Stonepeak and Evolve options 5,000,000 — Total 19,019,626 5,788,228

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Parties	Related Parties As described in Note 6 , the Company holds equity interests in and provides certain consulting services to Dreev, an entity in which a stockholder of the Company owns the other portion of Dreev’s equity interests. During the three months ended March 31, 2022 and 2021, the Company recognized re venue of $28,000 and $147,620, respectively, from an entity that is an investor in the Company. The Company had a balance of accounts receivable of $28,000 at March 31, 2022 from the same entity that is an investor in the Company. Equity Forward Purchase Pursuant to a letter agreement dated April 23,2021, the Company’s Chief Executive Officer and Chief Operating Officer committed to purchase from the Company, and the Company committed to sell to them, 134,499 shares of the Company’s common stock for $14.87 per share or a total of $2,000,000. The parties are committed to purchase the shares on or before April 23, 2022. As of April 23, Nuvve's Chief Operating Officer fulfilled his obligation and has purchased from Nuvve a total of 26,900 shares of the Company’s common stock for $14.87 per share. An extension up to June 15, 2022, has been granted and approved for Nuvve's Chief Executive Officer to complete his portion of the committed purchase of shares.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Leases The Company has entered into leases for commercial office spaces and vehicles. These leases are not unilaterally cancellable by the Company, are legally enforceable, and specify fixed or minimum amounts. The leases expire at various dates through 2026 and provide for renewal options. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. The leases provide for increases in future minimum annual rental payments based on defined increases in the Consumer Price Index, subject to certain minimum increases. Also, the agreements generally require the Company to pay real estate taxes, insurance, and repairs. Supplemental unaudited consolidated balance sheet information related to leases is as follows: Classification March 31, 2022 Operating lease assets Right-of-use operating lease assets $ 3,397,270 Finance lease assets Property, plant and equipment, net 23,550 Total lease assets $ 3,420,820 Operating lease liabilities - current Operating lease liabilities - current $ 254,057 Operating lease liabilities - noncurrent Operating lease liabilities - noncurrent 3,319,734 Finance lease liabilities - current Other liabilities - current 7,444 Finance lease liabilities - noncurrent Other long-term liabilities 17,283 Total lease liabilities $ 3,598,518 The components of lease expense are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2022 2021 Operating lease expense Selling, general and administrative $ 176,520 $ 58,431 Finance lease expense: Amortization of finance lease assets Selling, general and administrative 5,940 — Interest on finance lease liabilities Interest expense 639 — Total lease expense $ 183,099 $ 58,431 Operating Lease Finance Lease Maturities of lease liabilities are as follows: March 31, 2022 March 31, 2022 2022 $ 125,784 $ 5,583 2023 514,377 7,444 2024 529,807 7,444 2025 545,703 7,444 2026 562,074 — Thereafter 3,017,861 1,861 Total lease payments 5,295,606 29,776 Less: interest (1,721,815) (5,049) Total lease obligations $ 3,573,791 $ 24,727 Lease term and discount rate: March 31, 2022 Weighted-average remaining lease terms (in years): Operating lease 9.7 Finance lease 4.0 Weighted-average discount rate: Operating lease 7.8% Finance lease 7.8% Other Information: Three Months Ended March 31, Three Months Ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 62,269 $ — Operating cash flows from finance leases $ 639 $ — Financing cash flows from finance leases $ 2,073 $ — Leased assets obtained in exchange for new finance lease liabilities $ 23,550 $ — Leased assets obtained in exchange for new operating lease liabilities $ — $ — Main Office - Additional Lease Square footage On November 3, 2021, the Company entered into an amendment of its Main Office Lease to include an additional 4,811 rentable square feet in the suite adjoining its main office facilities in San Diego, California . The lease term will run concurrently with the main office lease which commenced in December 2021. The lease terms include 3% annual fixed increases in the base rental payment. Also, the lease requires the Company to pay operating expenses such as utilities, real estate taxes, insurance, and repairs. The lease term commenced on April 15, 2022, and the Company will receive two months of rental abatement to the base rent. The following is a maturity analysis of the annual undiscounted cash flows under new additional office lease for years ended December 31: 2022 $ 146,495 2023 256,785 2024 264,488 2025 272,423 2026 280,596 Thereafter 1,507,106 Total lease payments $ 2,727,893
Leases	Leases The Company has entered into leases for commercial office spaces and vehicles. These leases are not unilaterally cancellable by the Company, are legally enforceable, and specify fixed or minimum amounts. The leases expire at various dates through 2026 and provide for renewal options. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. The leases provide for increases in future minimum annual rental payments based on defined increases in the Consumer Price Index, subject to certain minimum increases. Also, the agreements generally require the Company to pay real estate taxes, insurance, and repairs. Supplemental unaudited consolidated balance sheet information related to leases is as follows: Classification March 31, 2022 Operating lease assets Right-of-use operating lease assets $ 3,397,270 Finance lease assets Property, plant and equipment, net 23,550 Total lease assets $ 3,420,820 Operating lease liabilities - current Operating lease liabilities - current $ 254,057 Operating lease liabilities - noncurrent Operating lease liabilities - noncurrent 3,319,734 Finance lease liabilities - current Other liabilities - current 7,444 Finance lease liabilities - noncurrent Other long-term liabilities 17,283 Total lease liabilities $ 3,598,518 The components of lease expense are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2022 2021 Operating lease expense Selling, general and administrative $ 176,520 $ 58,431 Finance lease expense: Amortization of finance lease assets Selling, general and administrative 5,940 — Interest on finance lease liabilities Interest expense 639 — Total lease expense $ 183,099 $ 58,431 Operating Lease Finance Lease Maturities of lease liabilities are as follows: March 31, 2022 March 31, 2022 2022 $ 125,784 $ 5,583 2023 514,377 7,444 2024 529,807 7,444 2025 545,703 7,444 2026 562,074 — Thereafter 3,017,861 1,861 Total lease payments 5,295,606 29,776 Less: interest (1,721,815) (5,049) Total lease obligations $ 3,573,791 $ 24,727 Lease term and discount rate: March 31, 2022 Weighted-average remaining lease terms (in years): Operating lease 9.7 Finance lease 4.0 Weighted-average discount rate: Operating lease 7.8% Finance lease 7.8% Other Information: Three Months Ended March 31, Three Months Ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 62,269 $ — Operating cash flows from finance leases $ 639 $ — Financing cash flows from finance leases $ 2,073 $ — Leased assets obtained in exchange for new finance lease liabilities $ 23,550 $ — Leased assets obtained in exchange for new operating lease liabilities $ — $ — Main Office - Additional Lease Square footage On November 3, 2021, the Company entered into an amendment of its Main Office Lease to include an additional 4,811 rentable square feet in the suite adjoining its main office facilities in San Diego, California . The lease term will run concurrently with the main office lease which commenced in December 2021. The lease terms include 3% annual fixed increases in the base rental payment. Also, the lease requires the Company to pay operating expenses such as utilities, real estate taxes, insurance, and repairs. The lease term commenced on April 15, 2022, and the Company will receive two months of rental abatement to the base rent. The following is a maturity analysis of the annual undiscounted cash flows under new additional office lease for years ended December 31: 2022 $ 146,495 2023 256,785 2024 264,488 2025 272,423 2026 280,596 Thereafter 1,507,106 Total lease payments $ 2,727,893

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Legal Matters The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities, including product liability claims. Management believes that any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the financial condition or results of operations of the Company. (b) Research Agreement Effective September 1, 2016, the Company is party to a research agreement with a third party, which is also a Company stockholder, whereby the third party will perform research activity as specified annually by the Company. Under the terms of the agreement, the Company paid a minimum of $400,000 annually in equal quarterly installments. For the three months ended March 31, 2022 and 2021, $100,000 each was paid under the research agreement, respectively. In October 2021, the agreement was renewed for one year through August 2022. At March 31, 2022, $166,667 remained to be paid under the renewed agreement. (c) In-Licensing The Company is a party to a licensing agreement for non-exclusive rights to intellectual property which will expire at the later of the date at which the last patent underlying the intellectual property expires or 20 years from the sale of the first licensed product. Under the terms of the agreement, the Company will pay up to an aggregate of $700,000 in royalties upon achievement of certain milestones. As of March 31, 2022 and December 31, 2021, no royalty expenses had been incurred under this agreement . In November 2017, the Company executed an agreement ("IP Acquisition Agreement") with the University of Delaware (Seller) whereby all right, title, and interest in the licensed intellectual property was assigned to the Company in exchange for an upfront fee of $500,000 and common shares valued at $1,491,556. The total acquisition cost of $1,991,556 was capitalized and is being amortized over the fifteen years expected life of the patents underlying the intellectual property. Under the terms of the agreement, the Company will pay up to an aggregate $7,500,000 in royalties to the Seller upon achievement of milestones, related to the aggregate number of vehicles that have had access to the Company’s GIVe platform system for a period of at least six consecutive months, and for which the Company has received monetary consideration for such access pursuant to a subscription or other similar agreement with the vehicle’s owner as follows: Milestone Event: Aggregated Vehicles Milestone 10,000 $ 500,000 20,000 750,000 40,000 750,000 60,000 750,000 80,000 750,000 100,000 1,000,000 200,000 1,000,000 250,000 2,000,000 $ 7,500,000 The Seller will retain a non-exclusive, royalty-free license, to utilize the intellectual property solely for research and education purposes. As of March 31, 2022, no royalty expenses had been incurred under this agreement. (d) Investment The Company is committed to possible future additional contributions to the Investment in Dreev ( Note 6 ) in the amount of $270,000. (e) Reimbursement of Legal Fees On October 5, 2020, the Company entered into an agreement with an investor whereby the Company agreed to reimburse the investor for certain legal fees, up to approximately $96,000 , associated with a license agreement between the parties. The reimbursement is payable upon the completion by the Company of an equity financing or the completion of the licensing agreement. No legal fees have been accrued or paid under this agreement through March 31, 2022.

Non-Controlling Interest

Non-Controlling Interest	3 Months Ended
	Mar. 31, 2022
Noncontrolling Interest [Abstract]
Non-Controlling Interest	Non-Controlling Interest For entities that are consolidated, but not 100% owned, a portion of the net income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the net income or loss and corresponding equity that is not owned by the Company is included in non-controlling interests in the condensed consolidated financial statements. Non-controlling interests are presented outside as a separate component of stockholders’ equity on the Company’s condensed consolidated Balance Sheets. The primary components of non-controlling interests are separately presented in the Company’s condensed consolidated statements of changes in stockholders’ equity to clearly distinguish the interest in the Company and other ownership interests in the consolidated entities. Net income or loss includes the net income or loss attributable to the holders of non-controlling interests on the Company’s condensed consolidated statements of operations. Net income or loss is allocated to non-controlling interests in proportion to their relative ownership interests. Levo Series B Redeemable Preferred Stock Levo is authorized to issue 1,000,000 shares of series B preferred stock at no par value. The Series B Preferred Stock (a) pays a dividend, when, as and if declared by Levo's Board of Directors, of 8.0% per annum of the stated value per share, payable quarterly in arrears, (b) has an initial stated value of $1,000 per share, and dividends are paid in cash. Levo accrues for undeclared and unpaid dividends as they are payable in accordance with the terms of the Certificate of Designations filed with the Secretary of State of the State of Delaware. At March 31, 2022, Levo had accrued preferred dividends of $126,775 on 3,138 issued and outstanding shares of Series B Preferred Stock. Series B Preferred Stock is not a participating or convertible securities. Series B Preferred Stock is not currently redeemable but it could be redeemable with the passage of time at the election of Levo or the preferred shareholders or upon the occurrence of a trigger event as defined in the preferred stock agreement. Since the redeemable preferred stock may be redeemed by the preferred shareholders or upon the occurrence of a trigger event that is not solely within the control of Levo, but is not mandatorily redeemable; therefore, based on its characteristics, Levo has classified the Series B Preferred Stock as mezzanine equity. At March 31, 2022, Series B Preferred Stock consisted of the following: Shares Authorized Shares Issued and Outstanding Stated Value per Share Initial Carrying Value Accrued Preferred Dividends Liquidation Preference 1,000,000 3,138 $ 1,000 $ 3,138,000 $ 126,775 $ 3,264,775 The Company has determined that the redemption features embedded in the non-controlling redeemable preferred stock is required to be accounted for separately from the redeemable preferred stock as a derivative liability. See Note 5 for detail disclosure of the derivative liability. The redeemable preferred stock has been classified as mezzanine equity and initially recognized at fair value of $3,138,000, the proceeds on the date of issuance. This amount has been further reduced by 0, the fair value of the embedded derivative liability at date of issuance, resulting in an adjusted initial value of $3,138,000. Levo is accreting the difference between the adjusted carrying initial value and the redemption price value over the seven-year period from date of issuance of August 4, 2021 through July 4, 2028 (the date at which the preferred shareholders have the unconditional right to redeem the shares, deemed to be the earliest likely redemption date) using the effective interest method. The accretion to the carrying value of the redeemable preferred stock is treated as a deemed dividend, recorded as a charge to retained earnings of Levo. During the quarter ended March 31, 2022, Levo accreted $161,466 resulting in the carrying value of the the redeemable preferred stock of $3,063,365. The following table summarizes Levo non-controlling interests presented as a separate component of stockholders’ equity on the Company’s condensed consolidated balance sheets at March 31, 2022: March 31, 2022 (Restated) (1) Add: net loss attributable to non-controlling interests as of March 31, 2022 $ (100,933) Less: dividends paid to non-controlling interests as of March 31, 2022 64,015 Less: Preferred share accretion adjustment 161,466 Non-controlling interests $ (326,414) The following table summarizes Levo non-controlling interests presented as a separate component of the Company’s condensed consolidated statements of operations as of March 31, 2022: Three Months Ended (Restated) (1) Net loss attributable to non-controlling interests $ (100,933) Redeemable Non-controlling Interest Reconciliation — Mezzanine Equity Three Months Ended (Restated) (1) Beginning balance - December 31, 2021 $ 2,901,899 Preferred share Accretion adjustment 161,466 Ending balance - March 31, 2022 $ 3,063,365

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In April 2022, the Company entered into a sublease agreement with a local San Diego company to sublease the Company's 4,811

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited (i) condensed consolidated balance sheet as of December 31, 2021, which has been derived from audited financial statements, and (ii) the unaudited interim condensed financial statements have been prepared in accordance pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Therefore, it is suggested that these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes in the 2021 Form 10-K, filed with the Securities and Exchange Commission ("SEC") on March 31, 2022. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, comprehensive loss, cash flows, and stockholders’ equity for the interim periods, but are not necessarily indicative of the results to be anticipated for the full year 2022 or any future period. In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the that the consolidated financial statements are issued. Since inception, the Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $97.6 million as of March 31, 2022. Nuvve incurred operating losses of approximately $9.5 million for the quarter ended March 31, 2022, and $27.2 million and $4.7 million for the years ended December 31, 2021, and 2020, respectively. As of March 31, 2022, Nuvve had a cash balance, working capital, and stockholders’ equity of $23.7 million, $28.8 million and $23.5 million, respectively. The Company continues to expect to generate operating losses and negative cash flows and may need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful expanded commercialization of the Company's GIVe platform and the achievement of a level of revenues adequate to support its cost structure. The Company expects its cash and cash equivalents as of May 12, 2022 will be sufficient to fund current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements. Management's expectations with respect to its ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. Actual results could be different from management's estimates and should actual results be less favorable than these estimates management would ultimately need to take corrective steps to improve future operating results and its financial condition. Restatement of Previously Issued Financial Statements Subsequent to the issuance of the company’s condensed consolidated financial statements as of March 2022 and 2021, errors were identified relating to the following: The associated income tax expense or benefit and related deferred tax assets or liabilities have been reflected, including the impact of valuation allowance. (1) Unvested warrants issued to Stonepeak and Evolve in May 2021, as described in Note 11, should be accounted for as a single unit of account as opposed to multiple units of account. As a result, these unvested warrants, which were previously recorded in equity, have been reclassified to liabilities on the consolidated balance sheet. As a single unit of account, the unvested warrants’ settlement value is impacted by the amount of capital expenditures associated with Levo’s customer contracts, which caused the unvested warrants to not be indexed to the Company's equity. The unvested warrant liability is adjusted to its estimated fair value at each reporting date. (2) As part of the fair value of warrants and stock option (“Instruments”) granted to Stonepeak and Evolve in May 2021, in conjunction with the formation of Levo, the Company inaccurately capitalized the costs incurred to deferred financing costs, and should have expensed such costs. The Company determined that there was not sufficient basis to record deferred financing costs associated with Stonepeak and Evolve’s plans to contribute capital to the Levo venture. As a result, the estimated fair value of the Instruments that were previously recorded as a capitalized asset are corrected to recognize an expense upon issuance of the Instruments during the second quarter of 2021. The expense is non-cash and does not impact the existing conditional capital commitment the Company has from Stonepeak and Evolve or the pursuit of customer deployments funded by this conditional capital commitment. The associated income tax expense or benefit and related deferred tax assets or liabilities have been reflected, including the impact of valuation allowance. The following tables summarize the effect of the aforementioned adjustments on the Company's Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021, and the Company's Condensed Consolidated Statement of Operations, and Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2022: Condensed Consolidated Balance Sheets March 31, 2022 March 31, 2022 Assets As Previously Reported Adjustment As Restated Deferred financing costs $ 43,562,847 $ (43,562,847) $ — Total Assets $ 86,520,460 $ (43,562,847) $ 42,957,613 Current Liabilities Warrants liability $ 458,476 $ 4,333,999 $ 4,792,475 Total Liabilities $ 12,062,586 $ 4,333,999 $ 16,396,585 Mezzanine equity Redeemable non-controlling interests, preferred shares, zero par value, 1,000,000 shares authorized, 3,138 shares issue and outstanding at March 31, 2022 and December 31, 2021; aggregate liquidation preference of $3,264,775 at March 31, 2022 $ 3,046,892 $ 16,472 $ 3,063,365 Stockholders’ (Deficit) Equity Additional paid-in capital $ 128,594,145 $ (4,801,897) $ 123,792,248 Accumulated deficit $ (56,385,798) $ (41,182,393) $ (97,568,191) Nuvve Stockholders’ Equity (Deficit) $ 72,310,000 $ (45,984,290) $ 26,325,710 Non-controlling interests $ (899,018) $ (1,929,029) $ (2,828,047) Total Stockholders’ Equity (Deficit) $ 71,410,982 $ (47,913,319) $ 23,497,663 Total Liabilities, Mezzanine equity and Stockholders’ Equity $ 86,520,460 $ (43,562,847) $ 42,957,613 Three Months Ended March 31, Three Months Ended March 31, 2022 2022 Condensed Consolidated Statement of Operations As Previously Reported Adjustment As Restated Change in fair value of warrants liability $ 433,000 $ 4,343,000 $ 4,776,000 Total other (expense) income, net $ 458,143 $ 4,343,000 $ 4,801,143 Loss before taxes $ (9,074,261) $ 4,343,000 $ (4,731,261) Net loss $ (9,074,261) $ 4,343,000 $ (4,731,261) Net loss attributable to Nuvve Holding Corp. $ (8,973,328) $ 4,343,000 $ (4,630,328) Net loss attributable to Nuvve common stockholders $ (9,198,809) $ 4,343,000 $ (4,855,809) Net loss per share attributable to Nuvve common stockholders, basic and diluted $ (0.49) $ 0.23 $ (0.26) Three Months Ended March 30, Three Months Ended March 30, 2022 2022 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS As Previously Reported Adjustment As Restated Net loss $ (9,074,261) 4,343,000 $ (4,731,261) Comprehensive loss attributable to Nuvve common stockholders $ (8,761,531) 4,343,000 $ (4,418,531) CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY As Previously Reported Adjustment As Restated Net Loss $ (9,074,261) $ 4,343,000 $ (4,731,261) Balance March 31, 2022 $ 71,410,982 $ (47,913,319) $ 23,497,663 Three Months Ended March 31, Three Months Ended March 31, 2022 2022 Condensed Consolidated Statement of Cash Flows As Previously Reported Adjustment As Restated Operating activities Net loss $ (9,074,261.00) $ 4,343,000.00 $ (4,731,261.00) Adjustments to reconcile to net loss to net cash used in operating activities Change in fair value of warrants liability $ (433,000.00) $ (4,343,000.00) $ (4,776,000.00) Net cash used in operating activities $ (8,449,889.00) $ — $ (8,449,889.00)
Principles of Consolidation	Principles of ConsolidationThe condensed consolidated financial statements include the accounts and operations of the Company, its wholly owned subsidiaries and its consolidated variable interest entity. All intercompany accounts and transactions have been eliminated upon consolidation.
Variable Interest Entities	Variable Interest Entities Pursuant to the consolidation guidance, the Company first evaluates whether it holds a variable interest in an entity in which it has a financial relationship and, if so, whether or not that entity is a variable interest entity ("VIE"). A VIE is an entity with insufficient equity at risk for the entity to finance its activities without additional subordinated financial support or in which equity investors lack the characteristics of a controlling financial interest. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company concludes that it is the primary beneficiary and consolidates the VIE if the Company has both (i) the power to direct the activities of the VIE that most significantly influence the VIE's economic performance, and (ii) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. The Company formed Levo with Stonepeak and Evolve, in which the Company owns 51% of Levo's common units. The Company has determined that Levo is a VIE in which the Company is the primary beneficiary. Accordingly, the Company consolidates Levo and records a non-controlling interest for the share of the entity owned by Stonepeak and Evolve. Assets and Liabilities of Consolidated VIEs The Company's condensed consolidated financial statements include the assets, liabilities and results of operations of VIEs for which the Company is the primary beneficiary. The other equity holders’ interests are reflected in "Net loss attributable to non-controlling interests" in the condensed consolidated statements of operations and "Non-controlling interests" in the condensed consolidated balance sheets. See Note 18 for details of non-controlling interests. The Company began consolidating the assets, liabilities and results of operations of Levo during the quarter ended March 31, 2022.
Noncontrolling Interest	Redeemable Non-Controlling Interest - Mezzanine Equity Redeemable non-controlling interest represents the shares of the preferred stock issued by Levo to Stonepeak and Evolve (the "preferred shareholders") who own 49% of Levo common units. The preferred stock is not mandatorily redeemable or currently redeemable, but it could be redeemable with the passage of time at the election of Levo, the preferred shareholders or a trigger event as defined in the preferred stock agreement. As a result of the contingent put right available to the preferred shareholders, the redeemable non-controlling interests in Levo are classified outside of permanent equity in the Company’s unaudited condensed consolidated balance sheets as mezzanine equity. The initial carrying value of the redeemable non-controlling interest is reported at the initial proceeds received on issuance date, reduced by the fair value of embedded derivatives resulting in an adjusted initial carrying value. The adjusted initial carrying value is further adjusted for the accretion of the difference with the redemption price value using the effective interest method. The accretion amount is a deemed dividend recorded against retained earnings or, in its absence, to additional-paid-in-capital. The carrying amount of the redeemable non-controlling interest is measured at the higher of the carrying amount adjusted each reporting period for income (or loss) attributable to the non-controlling interest, or the carrying amount adjusted each reporting period by the accretion amount. See Note 18 for details. Non-controlling interests The Company presents non-controlling interests as a component of equity on its condensed consolidated balance sheets and reports the portion of its earnings or loss for non-controlling interest as net earnings or loss attributable to non-controlling interests in the condensed consolidated statements of operations. For entities that are consolidated, but not 100% owned, a portion of the net income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the net income or loss and corresponding equity that is not owned by the Company is included in non-controlling interests in the condensed consolidated financial statements. Non-controlling interests are presented outside as a separate component of stockholders’ equity on the Company’s condensed consolidated Balance Sheets. The primary components of non-controlling interests are separately presented in the Company’s condensed consolidated statements of changes in stockholders’ equity to clearly distinguish the interest in the Company and other ownership interests in the consolidated entities. Net income or loss includes the net income or loss attributable to the holders of non-controlling interests on the Company’s condensed consolidated statements of operations. Net income or loss is allocated to non-controlling interests in proportion to their relative ownership interests.
Emerging Growth Company	Emerging Growth Company Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) permits emerging growth companies (“EGC”) to delay complying with new or revised financial accounting standards that do not yet apply to private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act). The Company qualifies as an EGC. The JOBS Act provides that an EGC can elect to opt-out of the extended transition period and comply with the requirements that apply to non-EGCs, but any such election to opt-out is irrevocable. The Company has elected not to opt-out of such an extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an EGC, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This different adoption timing may make a comparison of the Company’s financial statements with another public company which is neither an EGC nor an EGC that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
COVID-19	COVID-19 The novel coronavirus (COVID-19) which was declared a pandemic in March 2020, and the related restrictive measures such as travel restrictions, quarantines, and shutdowns, has negatively impacted the global economy. As national and local governments in different countries ease COVID-19 restrictions, and vaccines are distributed and rolled out successfully, we continue to see improved economic trends. However, COVID-19 and actions taken to mitigate its spread have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. The Company continues to monitor the situation closely but, at this time, is unable to predict the cumulative impact, both in terms of severity and duration, that the coronavirus pandemic has and will have on its business, operating results, cash flows and financial condition, and it could be material if the current circumstances continue to exist for a prolonged period of time. In addition to any direct impact on Nuvve’s business, it is reasonably possible that the estimates made by management in preparing Nuvve’s financial statements have been, or will be, materially and adversely impacted in the near term as a result of the on-going COVID-19 conditions.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include the impairment of intangible assets, the net realizable value of inventory, the fair value of share-based payments, the fair value of notes payable conversion options, revenue recognition, the fair value of warrants, and the recognition and disclosure of contingent liabilities. Management evaluates its estimates on an ongoing basis. Actual results could materially vary from those estimates.
Cash and Restricted Cash	Cash and Restricted Cash The Company maintains cash balances that can, at times, exceed amounts insured by the Federal Deposit Insurance Corporation, which is up to $250,000. The Company has not experienced any losses in these accounts and believes it is not exposed to any significant credit risk in this area.
Concentrations of Credit Risk	Concentrations of Credit Risk At March 31, 2022 and December 31, 2021, the financial instruments which potentially expose the Company to concentration of credit risk consist of cash in financial institutions (in excess of federally insured limits) and trade receivables. The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable, as follows: For the three months ended March 31, 2022 and 2021, one customer accounted for 72.8%, and two customers in aggregate accounted for 49.9% of revenue, respectively. During the three months ended March 31, 2022 and 2021 , the Company's top five customers accounted for approximately 87.5% and 71.4%, respectively, o f the Company’s total revenue. At March 31, 2022 , two customers in aggregate accounted for 35.7% of accounts receivable. At December 31, 2021 , two customers in aggregate accounted for 32.2% of accounts receivable. Approximately 58.7% and 56.0% of the Company’s trade accounts receivable balance was with five customers at March 31, 2022 and December 31, 2021 , respectively. The Company estimates its maximum credit risk for accounts receivable at the amount recorded on the balance sheet. The trade accounts receivables are generally short-term and all probable bad debt losses have been appropriately considered in establishing the allowance for doubtful accounts.
Recently adopted accounting pronouncements	Recently adopted accounting pronouncements None.
Recently issued accounting pronouncements not yet adopted	Recently issued accounting pronouncements not yet adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires, among other things, the use of a new current expected credit loss ("CECL") model in determining the allowances for doubtful accounts with respect to accounts receivable, accrued straight-line rents receivable, and notes receivable. The CECL model requires that an entity estimate its lifetime expected credit loss with respect to these receivables and record allowances that, when deducted from the balance of the receivables, represent the net amounts expected to be collected. Entities will also be required to disclose information about how the entity developed the allowances, including changes in the factors that influenced its estimate of expected credit losses and the reasons for those changes. This update is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of restatement of previously issued financial statements	The following tables summarize the effect of the aforementioned adjustments on the Company's Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021, and the Company's Condensed Consolidated Statement of Operations, and Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2022: Condensed Consolidated Balance Sheets March 31, 2022 March 31, 2022 Assets As Previously Reported Adjustment As Restated Deferred financing costs $ 43,562,847 $ (43,562,847) $ — Total Assets $ 86,520,460 $ (43,562,847) $ 42,957,613 Current Liabilities Warrants liability $ 458,476 $ 4,333,999 $ 4,792,475 Total Liabilities $ 12,062,586 $ 4,333,999 $ 16,396,585 Mezzanine equity Redeemable non-controlling interests, preferred shares, zero par value, 1,000,000 shares authorized, 3,138 shares issue and outstanding at March 31, 2022 and December 31, 2021; aggregate liquidation preference of $3,264,775 at March 31, 2022 $ 3,046,892 $ 16,472 $ 3,063,365 Stockholders’ (Deficit) Equity Additional paid-in capital $ 128,594,145 $ (4,801,897) $ 123,792,248 Accumulated deficit $ (56,385,798) $ (41,182,393) $ (97,568,191) Nuvve Stockholders’ Equity (Deficit) $ 72,310,000 $ (45,984,290) $ 26,325,710 Non-controlling interests $ (899,018) $ (1,929,029) $ (2,828,047) Total Stockholders’ Equity (Deficit) $ 71,410,982 $ (47,913,319) $ 23,497,663 Total Liabilities, Mezzanine equity and Stockholders’ Equity $ 86,520,460 $ (43,562,847) $ 42,957,613 Three Months Ended March 31, Three Months Ended March 31, 2022 2022 Condensed Consolidated Statement of Operations As Previously Reported Adjustment As Restated Change in fair value of warrants liability $ 433,000 $ 4,343,000 $ 4,776,000 Total other (expense) income, net $ 458,143 $ 4,343,000 $ 4,801,143 Loss before taxes $ (9,074,261) $ 4,343,000 $ (4,731,261) Net loss $ (9,074,261) $ 4,343,000 $ (4,731,261) Net loss attributable to Nuvve Holding Corp. $ (8,973,328) $ 4,343,000 $ (4,630,328) Net loss attributable to Nuvve common stockholders $ (9,198,809) $ 4,343,000 $ (4,855,809) Net loss per share attributable to Nuvve common stockholders, basic and diluted $ (0.49) $ 0.23 $ (0.26) Three Months Ended March 30, Three Months Ended March 30, 2022 2022 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS As Previously Reported Adjustment As Restated Net loss $ (9,074,261) 4,343,000 $ (4,731,261) Comprehensive loss attributable to Nuvve common stockholders $ (8,761,531) 4,343,000 $ (4,418,531) CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY As Previously Reported Adjustment As Restated Net Loss $ (9,074,261) $ 4,343,000 $ (4,731,261) Balance March 31, 2022 $ 71,410,982 $ (47,913,319) $ 23,497,663 Three Months Ended March 31, Three Months Ended March 31, 2022 2022 Condensed Consolidated Statement of Cash Flows As Previously Reported Adjustment As Restated Operating activities Net loss $ (9,074,261.00) $ 4,343,000.00 $ (4,731,261.00) Adjustments to reconcile to net loss to net cash used in operating activities Change in fair value of warrants liability $ (433,000.00) $ (4,343,000.00) $ (4,776,000.00) Net cash used in operating activities $ (8,449,889.00) $ — $ (8,449,889.00)
Schedule of assets and liabilities included in the company’s condensed consolidated balance sheets	The following table summarizes the carrying amounts of Levo assets and liabilities included in the Company’s condensed consolidated balance sheets at March 31, 2022: March 31, 2022 Assets Cash $ 28,257 Total Assets $ 28,257 Liabilities and Mezzanine Equity Accrued expenses $ 236,775 Derivative liability - non-controlling redeemable preferred shares 458,476 Total Liabilities $ 695,251

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of information regarding disaggregated revenue based on revenue by service	The following table provides information regarding disaggregated revenue based on revenue by service lines for the three months ended March 31: Three Months Ended March 31, 2022 2021 Revenue recognized over time: Services $ 194,650 $ 167,245 Grants 117,249 487,129 Products 2,059,134 144,658 Total revenue $ 2,371,033 $ 799,032
Schedule of aggregate amount of revenue for the Company’s existing contracts with customers	The aggregate amount of revenue for the Company’s existing contracts with customers as of March 31, 2022 expected to be recognized in the future, and classified as deferred revenue on the condensed consolidated Balance Sheet, for years ended December 31, is as follows (this disclosure does not include revenue related to contracts whose original expected duration is one year or less): 2022 (remaining nine months) $ 540,331 Thereafter 150,537 Total $ 690,868
Schedule of company operates in a single business segment	The following table summarizes the Company’s revenues for the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 Revenues: United States $ 2,227,734 $ 591,831 United Kingdom 37,390 141,286 Denmark 105,909 65,915 $ 2,371,033 $ 799,032 The following table summarizes the Company’s long-lived assets in different geographic locations as of March 31, 2022 and December 31, 2021: March 31, December 31, Long-lived assets: United States $ 1,948,891 $ 1,811,607 Denmark 23,550 25,664 $ 1,972,441 $ 1,837,271

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of liabilities measured at fair value on the condensed consolidated balance sheet	The following are the liabilities measured at fair value on the condensed consolidated balance sheet at March 31, 2022 using quoted price in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3): Level 1: Level 2: Level 3: Total at March 31, Total Gains (Losses) For The Three Months Ended March 31, 2022 Recurring fair value measurements Private warrants $ — $ — $ 433,000 $ 433,000 $ 433,000 Stonepeak and Evolve unvested warrants $ — $ — $ 4,334,000 $ 4,334,000 $ 4,343,000 Derivative liability - non-controlling redeemable preferred shares $ — $ — $ 458,476 $ 458,476 $ 53,472 Total recurring fair value measurements $ — $ — $ 5,225,476 $ 5,225,476 $ 4,829,472
Schedule of fair value on a recurring basis	The following is a reconciliation of the opening and closing balances for the liabilities related to the warrants (Note 11) and derivative liability - non-controlling redeemable preferred shares measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2022: Private Warrants Stonepeak and Evolve unvested warrants Non-controlling redeemable preferred shares - derivative liability (Restated) (1) Balance at December 31, 2021 $ 866,000 $ 8,677,000 $ 511,948 Total (gains) losses for period included in earnings (433,000) (4,343,000) (53,472) Balance at March 31, 2022 $ 433,000 $ 4,334,000 $ 458,476
Schedule of fair value measurement inputs and valuation techniques	The following table presents the significant unobservable inputs and valuation methodologies used for the Company’s fair value measurements of non-recurring (level 3) Stonepeak and Evolve unvested warrants: Series C Unvested Warrants Series D Unvested Warrants Series E Unvested Warrants Series F Unvested Warrants Fair value (in millions) $1.7 $1.2 $0.8 $0.6 Valuation methodology Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Monte Carlo Simulation & Black Scholes Term (years) 9.10 9.10 9.10 9.10 Risk free rate 2.3% 2.3% 2.3% 2.3% Exercise price $15.0 $20.0 $30.0 $40.0 Volatility 56.0% 56.0% 56.0% 56.0% Capital expenditure forecast (in millions) $125.0 $250.0 $375.0 $500.0 Probability of warrants vesting 90.8% 76.0% 63.8% 54.4%

Derivative Liability - Non-Co_2

Derivative Liability - Non-Controlling Redeemable Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liabilities at Fair Value	The following table display the fair value of derivatives by balance sheet line item at March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 Other long term liabilities: Derivative liability - non-controlling redeemable preferred shares $ 458,476 $ 511,948

Account Receivables, Net (Table

Account Receivables, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Schedule of accounts receivable	The following tables summarizes the Company's accounts receivable on the consolidated balance sheets at March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 Trade receivables $ 1,494,322 $ 1,949,896 Less: allowance for doubtful accounts (63,188) (63,188) Accounts receivable, net $ 1,431,134 $ 1,886,708 Allowance for doubtful accounts: Balance December 31, 2021 $ (63,188) Provision — Write-off — Recoveries — Balance March 31, 2022 $ (63,188)

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of inventory by category	The following table summarizes the Company’s inventories balance by category: March 31, 2022 December 31, 2021 DC Chargers $ 7,431,300 $ 7,687,598 AC Chargers 204,687 232,920 Vehicles - School Buses (1) 1,620,000 3,180,000 Others 72,219 17,670 Total $ 9,328,206 $ 11,118,188 __________________ (1) As of March 31, 2022, the Company has taken delivery of ten school buses it has committed to purchase from the manufacturer within one year from the purchase order date of May 26, 2021. During the first quarter ended March 31, 2022, five school buses were sold.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	The following table summarizes the Company’s property, plant and equipment balance at March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 Computers & Servers $ 113,490 $ 105,499 Vehicles 168,862 168,862 Office furniture and equipment 317,546 161,771 Others 93,146 6,050 Total 693,044 442,182 Less: Accumulated Depreciation (120,545) (85,988) Property, plant and equipment, net $ 572,499 $ 356,194 March 31, 2022 March 31, 2021 Depreciation expense $ 25,975 $ 6,508

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of estimated future amortization expense amortizable intangible assets	Total estimated future amortization expense is as follows: 2022 (remaining nine months) $ 104,577 2023 139,437 2024 139,437 2025 139,437 2026 139,437 Thereafter 783,893 $ 1,446,218

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule of common stock issuable upon exercise of warrants outstanding	The following table is a summary of the number of shares of the Company’s Common Stock issuable upon exercise of warrants outstanding at March 31, 2022 (there were no warrants outstanding at December 31, 2021): Number of Number of Exercise Expiration Public Warrants 2,875,000 2,875,000 $11.50 March 19, 2026 Private Warrants 136,250 136,250 $11.50 March 19, 2026 PIPE Warrants 1,353,750 1,353,750 $11.50 March 19, 2026 Stonepeak/Evolve Warrants - series B 2,000,000 2,000,000 $10.00 May 17, 2031 Stonepeak/Evolve Warrants - series C 1,000,000 500,000 $15.00 May 17, 2031 Stonepeak/Evolve Warrants - series D 1,000,000 500,000 $20.00 May 17, 2031 Stonepeak/Evolve Warrants - series E 1,000,000 500,000 $30.00 May 17, 2031 Stonepeak/Evolve Warrants - series F 1,000,000 500,000 $40.00 May 17, 2031 10,365,000 8,365,000

Stock Option Plan (Tables)

Stock Option Plan (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense for stock options	Stock-based compensation expense for the three months ended March 31 are as follows Three Months Ended March 31, 2022 2021 Options $ 822,106 $ 262,105 Restricted stock 613,839 — Total $ 1,435,945 $ 262,105
Schedule of black-scholes option pricing model to estimate the fair value of stock options	The following assumptions were used in the Black-Scholes model to calculate the fair value of stock options granted for the three months ended March 31, 2022 for the 2010 Plan and the 2020 Plan. 2010 Plan 2020 Plan Expected life of options (in years) (1) 6.1 6.1 Dividend yield (2) 0 % 0 % Risk-free interest rate (3) 2.00 % 2.00 % Volatility (4) 54.4 % 54.4 % __________________ (1) The expected life of options is the average of the contractual term of the options and the vesting period. (2) No cash dividends have been declared on the Company’s common stock since the Company’s inception, and the Company currently does not anticipate declaring or paying cash dividends over the expected life of the options. (3) The risk-free interest rate is based on the yields on U.S. Treasury debt securities with maturities approximating the estimated life of the options. (4) Volatility is estimated by management. As the Company has been a private company for most of its existence, there is not enough historical volatility data related to the Company’s Common stock as a public entity. Therefore, this estimate is based on the average volatility of certain public company peers within the Company’s industry.
Schedule of stock option activity	The following is a summary of the stock option activity under the 2010 Plan, as converted to the Company’s shares due to Reverse Recapitalization, for the three months ended March 31, 2022: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2021 1,035,035 3.21 5.90 5,688,201 Granted — — — — Exercised — — — — Forfeited — — — — Expired/Cancelled (5,310) 1.37 — — Outstanding - March 31, 2022 1,029,725 3.22 5.69 5,649,500 Options Exercisable at March 31, 2022 857,024 2.43 5.14 5,344,262 Option Vested at March 31, 2022 857,024 2.43 5.14 5,344,262 The weighted-average grant-date fair value of options granted during the three months ended March 31, 2022 was zero. The following is a summary of the stock option activity under the 2020 Plan for the three months ended March 31, 2022: Shares Weighted- Weighted- Aggregate Intrinsic Value($) Outstanding - December 31, 2021 1,602,850 13.18 9.27 46,920 Granted 106,000 6.77 9.86 — Exercised — — — — Forfeited — — — — Expired/Cancelled — — — — Outstanding - March 31, 2022 1,708,850 12.78 9.07 252,560 Options Exercisable at March 31, 2022 330,062 13.70 — — Option Vested at March 31, 2022 330,062 13.70 — —
Disclosure of share-based compensation arrangements by share-based payment award	Other Information: Three Months Ended 2022 2021 Amount received from option exercised $ — $ — March 31, 2022 Weighted average remaining recognition period Total unrecognized options compensation costs $ 9,987,990 2.98
Schedule of nonvested restricted stock units	A summary of the status of the Company’s nonvested restricted stock units as of December 31, 2021, and changes during the three months ended March 31, 2022, is presented below: Shares Weighted- Nonvested at December 31, 2021 353,817 11.00 Granted 27,478 10.15 Vested/Release (30,370) 13.79 Cancelled/Forfeited — — Nonvested and Outstanding at March 31, 2022 350,925 10.70

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of income tax information	Three Months Ended March 31, 2022 2021 Income tax (benefit) expense $ — $ — Effective tax rate 0.0 % (0.1) %

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of earnings per share	The following table sets forth the calculation of basic and diluted net loss per share attributable to common stockholders during the three months ended March 31, 2022 and 2021: Three Months Ended March 31, 2022 2021 (Restated) (1) Net loss attributable to Nuvve common stockholders $ (4,855,809) $ (5,361,720) Weighted-average shares used to compute net loss per share attributable to Nuvve common stockholders, basic and diluted 18,864,374 10,408,080 Net Loss per share attributable to Nuvve common stockholders, basic and diluted $ (0.26) $ (0.52) (1) As described in Note 2 to these condensed Consolidated Financial Statements, the Company has restated the condensed Consolidated Financial Statements.
Schedule of antidilutive securities excluded from the computation of earnings per share	The following outstanding shares of common stock equivalents were excluded from the calculation of the diluted net loss per share attributable to Nuvve common stockholders because their effect would have been anti-dilutive: Three Months Ended March 31, 2022 2021 Stock options issued and outstanding 2,773,734 1,415,355 Nonvested restricted stock issued and outstanding 880,892 7,873 Public warrants 2,875,000 2,875,000 Private warrants 136,250 136,250 PIPE warrants 1,353,750 1,353,750 Stonepeak and Evolve warrants 6,000,000 — Stonepeak and Evolve options 5,000,000 — Total 19,019,626 5,788,228

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Lease costs	Supplemental unaudited consolidated balance sheet information related to leases is as follows: Classification March 31, 2022 Operating lease assets Right-of-use operating lease assets $ 3,397,270 Finance lease assets Property, plant and equipment, net 23,550 Total lease assets $ 3,420,820 Operating lease liabilities - current Operating lease liabilities - current $ 254,057 Operating lease liabilities - noncurrent Operating lease liabilities - noncurrent 3,319,734 Finance lease liabilities - current Other liabilities - current 7,444 Finance lease liabilities - noncurrent Other long-term liabilities 17,283 Total lease liabilities $ 3,598,518 The components of lease expense are as follows: Three Months Ended March 31, Three Months Ended March 31, Classification 2022 2021 Operating lease expense Selling, general and administrative $ 176,520 $ 58,431 Finance lease expense: Amortization of finance lease assets Selling, general and administrative 5,940 — Interest on finance lease liabilities Interest expense 639 — Total lease expense $ 183,099 $ 58,431 Lease term and discount rate: March 31, 2022 Weighted-average remaining lease terms (in years): Operating lease 9.7 Finance lease 4.0 Weighted-average discount rate: Operating lease 7.8% Finance lease 7.8% Other Information: Three Months Ended March 31, Three Months Ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 62,269 $ — Operating cash flows from finance leases $ 639 $ — Financing cash flows from finance leases $ 2,073 $ — Leased assets obtained in exchange for new finance lease liabilities $ 23,550 $ — Leased assets obtained in exchange for new operating lease liabilities $ — $ —
Lessee, operating lease, liability, maturity	Operating Lease Finance Lease Maturities of lease liabilities are as follows: March 31, 2022 March 31, 2022 2022 $ 125,784 $ 5,583 2023 514,377 7,444 2024 529,807 7,444 2025 545,703 7,444 2026 562,074 — Thereafter 3,017,861 1,861 Total lease payments 5,295,606 29,776 Less: interest (1,721,815) (5,049) Total lease obligations $ 3,573,791 $ 24,727 The following is a maturity analysis of the annual undiscounted cash flows under new additional office lease for years ended December 31: 2022 $ 146,495 2023 256,785 2024 264,488 2025 272,423 2026 280,596 Thereafter 1,507,106 Total lease payments $ 2,727,893
Finance lease, liability, maturity	Operating Lease Finance Lease Maturities of lease liabilities are as follows: March 31, 2022 March 31, 2022 2022 $ 125,784 $ 5,583 2023 514,377 7,444 2024 529,807 7,444 2025 545,703 7,444 2026 562,074 — Thereafter 3,017,861 1,861 Total lease payments 5,295,606 29,776 Less: interest (1,721,815) (5,049) Total lease obligations $ 3,573,791 $ 24,727

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of milestone event	Under the terms of the agreement, the Company will pay up to an aggregate $7,500,000 in royalties to the Seller upon achievement of milestones, related to the aggregate number of vehicles that have had access to the Company’s GIVe platform system for a period of at least six consecutive months, and for which the Company has received monetary consideration for such access pursuant to a subscription or other similar agreement with the vehicle’s owner as follows: Milestone Event: Aggregated Vehicles Milestone 10,000 $ 500,000 20,000 750,000 40,000 750,000 60,000 750,000 80,000 750,000 100,000 1,000,000 200,000 1,000,000 250,000 2,000,000 $ 7,500,000

Non-Controlling Interest (Table

Non-Controlling Interest (Tables)	3 Months Ended
	Mar. 31, 2022
Noncontrolling Interest [Abstract]
Schedule of preferred stock	At March 31, 2022, Series B Preferred Stock consisted of the following: Shares Authorized Shares Issued and Outstanding Stated Value per Share Initial Carrying Value Accrued Preferred Dividends Liquidation Preference 1,000,000 3,138 $ 1,000 $ 3,138,000 $ 126,775 $ 3,264,775
Schedule of condensed financial statements	The following table summarizes Levo non-controlling interests presented as a separate component of stockholders’ equity on the Company’s condensed consolidated balance sheets at March 31, 2022: March 31, 2022 (Restated) (1) Add: net loss attributable to non-controlling interests as of March 31, 2022 $ (100,933) Less: dividends paid to non-controlling interests as of March 31, 2022 64,015 Less: Preferred share accretion adjustment 161,466 Non-controlling interests $ (326,414)
Schedule of condensed income statement	The following table summarizes Levo non-controlling interests presented as a separate component of the Company’s condensed consolidated statements of operations as of March 31, 2022: Three Months Ended (Restated) (1) Net loss attributable to non-controlling interests $ (100,933)
Schedule of redeemable noncontrolling interest	Redeemable Non-controlling Interest Reconciliation — Mezzanine Equity Three Months Ended (Restated) (1) Beginning balance - December 31, 2021 $ 2,901,899 Preferred share Accretion adjustment 161,466 Ending balance - March 31, 2022 $ 3,063,365

Organization and Description _2

Organization and Description of Business (Details)	Mar. 31, 2022 member
Nuvve
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of wholly owned subsidiaries	2
Nuvve Corp.
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of wholly owned subsidiaries	3

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)		3 Months Ended			12 Months Ended
		Mar. 31, 2022		Mar. 31, 2021	Dec. 31, 2021		Dec. 31, 2020
Summary of Significant Accounting Policies [Line Items]
Accumulated deficit	[1]	$ (97,568,191)			$ (92,937,863)
Operating loss		(9,532,404)	[2]	$ (5,073,886)
Net loss		(4,731,261)	[2],[3],[4],[5]	(5,361,720)	27,200,000		$ 4,700,000
Cash		23,704,646	[6]		32,360,520	[1]
Working capital		28,800,000
Stockholders' equity		23,497,663	[1],[5]	$ 57,394,610	$ 27,012,445	[1],[5]	$ (880,710)
FDIC amount		250,000
Levo Mobility LLC | Variable Interest Entity
Summary of Significant Accounting Policies [Line Items]
Cash		$ 28,257
Variable interest entity		51%
Levo Mobility LLC | Stonepeak
Summary of Significant Accounting Policies [Line Items]
Stonepeak and Evolve 49% ownership		49%
[1]See Note 2.[2]See Note 2.[3](1) See Note 2.[4]Note 2.[5]See Note 2[6]See Note 2.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Restatement of Previously Issued Financial Statements - Condensed Consolidated Balance Sheet (Details) - USD ($)		Mar. 31, 2022		Dec. 31, 2021		Mar. 31, 2021	Dec. 31, 2020
Assets
Deferred financing costs		$ 0
Total Assets	[1]	42,957,613		$ 52,914,543
Liabilities
Warrants liability	[1]	4,792,475		9,543,000
Total Liabilities	[1]	16,396,585		23,000,199
Mezzanine equity
Redeemable non-controlling interests, preferred shares, zero par value, 1,000,000 shares authorized, 3,138 shares issue and outstanding at March 31, 2022 and December 31, 2021; aggregate liquidation preference of $3,264,775 at March 31, 2022	[1]	3,063,365		2,901,899
Stockholders’ (Deficit) Equity
Additional paid-in capital	[1]	123,792,248		122,336,607
Accumulated deficit	[1]	(97,568,191)		(92,937,863)
Nuvve Stockholders’ Equity (Deficit)	[1]	26,325,710		29,514,078
Non-controlling interests	[1]	(2,828,047)		(2,501,633)
Total Stockholders’ Equity (Deficit)		23,497,663	[1],[2]	27,012,445	[1],[2]	$ 57,394,610	$ (880,710)
Total Liabilities, Mezzanine equity and Stockholders’ Equity	[1]	$ 42,957,613		$ 52,914,543
Temporary equity, par value (in Dollars per share)		$ 0
Temporary equity, shares authorized (in Shares)		1,000,000
Temporary equity, shares issued (in Shares)		3,138		3,138
Temporary equity, shares outstanding (in Shares)		3,138		3,138
Temporary equity, liquidation preference		$ 3,264,775
As Previously Reported
Assets
Deferred financing costs		43,562,847
Total Assets		86,520,460
Liabilities
Warrants liability		458,476
Total Liabilities		12,062,586
Mezzanine equity
Redeemable non-controlling interests, preferred shares, zero par value, 1,000,000 shares authorized, 3,138 shares issue and outstanding at March 31, 2022 and December 31, 2021; aggregate liquidation preference of $3,264,775 at March 31, 2022		3,046,892
Stockholders’ (Deficit) Equity
Additional paid-in capital		128,594,145
Accumulated deficit		(56,385,798)
Nuvve Stockholders’ Equity (Deficit)		72,310,000
Non-controlling interests		(899,018)
Total Stockholders’ Equity (Deficit)		71,410,982
Total Liabilities, Mezzanine equity and Stockholders’ Equity		86,520,460
Adjustment
Assets
Deferred financing costs		(43,562,847)
Total Assets		(43,562,847)
Liabilities
Warrants liability		4,333,999
Total Liabilities		4,333,999
Mezzanine equity
Redeemable non-controlling interests, preferred shares, zero par value, 1,000,000 shares authorized, 3,138 shares issue and outstanding at March 31, 2022 and December 31, 2021; aggregate liquidation preference of $3,264,775 at March 31, 2022		16,472
Stockholders’ (Deficit) Equity
Additional paid-in capital		(4,801,897)
Accumulated deficit		(41,182,393)
Nuvve Stockholders’ Equity (Deficit)		(45,984,290)
Non-controlling interests		(1,929,029)
Total Stockholders’ Equity (Deficit)		(47,913,319)
Total Liabilities, Mezzanine equity and Stockholders’ Equity		$ (43,562,847)
[1]See Note 2.[2]See Note 2

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Restatement of Previously Issued Financial Statements - Condensed Consolidated Statements of Operations (Details) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2022		Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Change in fair value of warrants liability	$ 4,776,000	[1],[2]	$ 421,830
Total other (expense) income, net	4,801,143	[2]	(287,834)
Loss before taxes	(4,731,261)	[2]	(5,361,720)
Net loss	(4,731,261)	[1],[2],[3],[4]	(5,361,720)	$ 27,200,000	$ 4,700,000
Net loss attributable to Nuvve Holding Corp.	(4,630,328)	[2]	(5,361,720)
Net loss attributable to Nuvve common stockholders, basic	$ (4,855,809)	[2]	$ (5,361,720)
Net loss per share attributable to Nuvve common stockholders, basic (in Dollars per share)	$ (0.26)	[2]	$ (0.52)
Net loss per share attributable to Nuvve common stockholders, diluted (in Dollars per share)	$ (0.26)	[2]	$ (0.52)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Change in fair value of warrants liability	$ 433,000
Total other (expense) income, net	458,143
Loss before taxes	(9,074,261)
Net loss	(9,074,261)
Net loss attributable to Nuvve Holding Corp.	(8,973,328)
Net loss attributable to Nuvve common stockholders, basic	$ (9,198,809)
Net loss per share attributable to Nuvve common stockholders, basic (in Dollars per share)	$ (0.49)
Net loss per share attributable to Nuvve common stockholders, diluted (in Dollars per share)	$ (0.49)
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Change in fair value of warrants liability	$ 4,343,000
Total other (expense) income, net	4,343,000
Loss before taxes	4,343,000
Net loss	4,343,000
Net loss attributable to Nuvve Holding Corp.	4,343,000
Net loss attributable to Nuvve common stockholders, basic	$ 4,343,000
Net loss per share attributable to Nuvve common stockholders, basic (in Dollars per share)	$ 0.23
Net loss per share attributable to Nuvve common stockholders, diluted (in Dollars per share)	$ 0.23
[1](1) See Note 2.[2]See Note 2.[3]Note 2.[4]See Note 2

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Restatement of Previously Issued Financial Statements - Condensed Consolidated Statements of Comprehensive Loss (Details) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2022		Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (4,731,261)	[1],[2],[3],[4]	$ (5,361,720)	$ 27,200,000	$ 4,700,000
Comprehensive loss attributable to Nuvve common stockholders	(4,418,531)	[2]	$ (5,244,971)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(9,074,261)
Comprehensive loss attributable to Nuvve common stockholders	(8,761,531)
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	4,343,000
Comprehensive loss attributable to Nuvve common stockholders	$ 4,343,000
[1](1) See Note 2.[2]Note 2.[3]See Note 2[4]See Note 2.

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Restatement of Previously Issued Financial Statements - Condensed Consolidated Statements of Stockholders' Equity (Details) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2022		Mar. 31, 2021	Dec. 31, 2021		Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (4,731,261)	[1],[2],[3],[4]	$ (5,361,720)	$ 27,200,000		$ 4,700,000
Balance March 31, 2022	23,497,663	[3],[5]	$ 57,394,610	$ 27,012,445	[3],[5]	$ (880,710)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(9,074,261)
Balance March 31, 2022	71,410,982
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	4,343,000
Balance March 31, 2022	$ (47,913,319)
[1](1) See Note 2.[2]Note 2.[3]See Note 2[4]See Note 2.[5]See Note 2.

Summary of Significant Accoun_9

Summary of Significant Accounting Policies -Restatement of Previously Issued Financial Statements - Condensed Consolidated Statements of Cash Flows (Details) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2022		Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net loss	$ (4,731,261)	[1],[2],[3],[4]	$ (5,361,720)	$ 27,200,000	$ 4,700,000
Adjustments to reconcile to net loss to net cash used in operating activities
Change in fair value of warrants liability	(4,776,000)	[1],[4]	(421,830)
Net cash used in operating activities	(8,449,889)	[1]	$ (2,633,851)
As Previously Reported
Operating activities
Net loss	(9,074,261)
Adjustments to reconcile to net loss to net cash used in operating activities
Change in fair value of warrants liability	(433,000)
Net cash used in operating activities	(8,449,889)
Adjustment
Operating activities
Net loss	4,343,000
Adjustments to reconcile to net loss to net cash used in operating activities
Change in fair value of warrants liability	(4,343,000)
Net cash used in operating activities	$ 0
[1](1) See Note 2.[2]Note 2.[3]See Note 2[4]See Note 2.

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Assets and liabilities of consolidated VIEs (Details) - USD ($)		Mar. 31, 2022		Dec. 31, 2021
Assets
Cash		$ 23,704,646	[1]	$ 32,360,520	[2]
Total Assets	[2]	42,957,613		52,914,543
Liabilities, Mezzanine Equity and Stockholders’ Equity
Accrued expenses	[2]	3,564,224		2,874,018
Derivative liability - non-controlling redeemable preferred shares	[2]	433,000		511,948
Total Liabilities	[2]	16,396,585		$ 23,000,199
Variable Interest Entity | Levo Mobility LLC
Assets
Cash		28,257
Total Assets		28,257
Liabilities, Mezzanine Equity and Stockholders’ Equity
Accrued expenses		236,775
Derivative liability - non-controlling redeemable preferred shares		458,476
Total Liabilities		$ 695,251
[1]See Note 2.[2]See Note 2.

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) - Customer Concentration Risk	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue Benchmark | 1 Customer
Revenue, Major Customer [Line Items]
Concentration risk	72.80%	72.80%
Revenue Benchmark | 2 Customers
Revenue, Major Customer [Line Items]
Concentration risk	49.90%	49.90%
Revenue Benchmark | Top 5 Customers
Revenue, Major Customer [Line Items]
Concentration risk	87.50%	71.40%
Accounts Receivable | 2 Customers
Revenue, Major Customer [Line Items]
Concentration risk	35.70%		32.20%
Accounts Receivable | Top 5 Customers
Revenue, Major Customer [Line Items]
Concentration risk	58.70%		56%

Revenue Recognition - Schedule

Revenue Recognition - Schedule of information regarding disaggregated revenue based on revenue by service (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022		Mar. 31, 2021
Deferred Revenue Arrangement [Line Items]
Total revenue	$ 2,371,033	[1]	$ 799,032
Services
Deferred Revenue Arrangement [Line Items]
Total revenue	194,650		167,245
Grants
Deferred Revenue Arrangement [Line Items]
Total revenue	117,249	[1]	487,129
Products
Deferred Revenue Arrangement [Line Items]
Total revenue	$ 2,059,134		$ 144,658
[1]See Note 2.

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of aggregate amount of revenue for the Company’s existing contracts with customers (Details)	Mar. 31, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 690,868
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 540,331
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 150,537
Revenue, remaining performance obligation, expected timing of satisfaction, period

Revenue Recognition - Schedul_3

Revenue Recognition - Schedule of segment reporting (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenues	$ 2,371,033	$ 799,032
Long-lived assets	1,972,441		$ 1,837,271
United States
Segment Reporting Information [Line Items]
Revenues	2,227,734	591,831
Long-lived assets	1,948,891		1,811,607
United Kingdom
Segment Reporting Information [Line Items]
Revenues	37,390	141,286
Denmark
Segment Reporting Information [Line Items]
Revenues	105,909	$ 65,915
Long-lived assets	$ 23,550		$ 25,664

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of liabilities measured at fair value on the condensed consolidated balance sheet (Details)	3 Months Ended
	Mar. 31, 2022 USD ($)
Recurring fair value measurements
Total recurring fair value measurements	$ 5,225,476
Recurring fair value measurements, gain (loss) during period	4,829,472
Derivative liability - non-controlling redeemable preferred shares
Recurring fair value measurements
Total recurring fair value measurements	458,476
Recurring fair value measurements, gain (loss) during period	53,472
Private Warrants
Recurring fair value measurements
Total recurring fair value measurements	433,000
Recurring fair value measurements, gain (loss) during period	433,000
Stonepeak and Evolve Warrants (Restated)
Recurring fair value measurements
Total recurring fair value measurements	4,334,000
Recurring fair value measurements, gain (loss) during period	4,343,000
Level 1: Quoted Prices in Active Markets for Identical Assets
Recurring fair value measurements
Total recurring fair value measurements	0
Level 1: Quoted Prices in Active Markets for Identical Assets | Derivative liability - non-controlling redeemable preferred shares
Recurring fair value measurements
Total recurring fair value measurements	0
Level 1: Quoted Prices in Active Markets for Identical Assets | Private Warrants
Recurring fair value measurements
Total recurring fair value measurements	0
Level 1: Quoted Prices in Active Markets for Identical Assets | Stonepeak and Evolve Warrants (Restated)
Recurring fair value measurements
Total recurring fair value measurements	0
Level 2: Significant Other Observable Inputs
Recurring fair value measurements
Total recurring fair value measurements	0
Level 2: Significant Other Observable Inputs | Derivative liability - non-controlling redeemable preferred shares
Recurring fair value measurements
Total recurring fair value measurements	0
Level 2: Significant Other Observable Inputs | Private Warrants
Recurring fair value measurements
Total recurring fair value measurements	0
Level 2: Significant Other Observable Inputs | Stonepeak and Evolve Warrants (Restated)
Recurring fair value measurements
Total recurring fair value measurements	0
Level 3: Significant Unobservable Inputs
Recurring fair value measurements
Total recurring fair value measurements	5,225,476
Level 3: Significant Unobservable Inputs | Derivative liability - non-controlling redeemable preferred shares
Recurring fair value measurements
Total recurring fair value measurements	458,476
Level 3: Significant Unobservable Inputs | Private Warrants
Recurring fair value measurements
Total recurring fair value measurements	433,000
Level 3: Significant Unobservable Inputs | Stonepeak and Evolve Warrants (Restated)
Recurring fair value measurements
Total recurring fair value measurements	$ 4,334,000

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of fair value on a recurring basis (Details)	3 Months Ended
	Mar. 31, 2022 USD ($)
Derivative liability - non-controlling redeemable preferred shares
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ 511,948
Total (gains) losses for period included in earnings	(53,472)
Balance	458,476
Private Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	866,000
Total (gains) losses for period included in earnings	(433,000)
Balance	433,000
Stonepeak Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	8,677,000
Total (gains) losses for period included in earnings	(4,343,000)
Balance	$ 4,334,000

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Fair Value Measurement Inputs and Techniques (Details)	Mar. 31, 2022 USD ($) $ / shares	May 17, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 5,225,476
Warrants outstanding, term		10 years
Series C Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 15
Series D Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share) | $ / shares	20
Series E Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share) | $ / shares	30
Series F Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 40
Level 3: Significant Unobservable Inputs
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 5,225,476
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series C Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 1,700,000
Warrants outstanding, term	9 years 1 month 6 days
Exercise price (in Dollars per share) | $ / shares	$ 15
Capital expenditure forecast (in millions)	$ 125,000,000
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series C Unvested Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.023
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series C Unvested Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series C Unvested Warrants | Measurement Input, Probability of Warrants Vesting
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.908
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series D Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 1,200,000
Warrants outstanding, term	9 years 1 month 6 days
Exercise price (in Dollars per share) | $ / shares	$ 20
Capital expenditure forecast (in millions)	$ 250,000,000
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series D Unvested Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.023
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series D Unvested Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series D Unvested Warrants | Measurement Input, Probability of Warrants Vesting
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.760
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series E Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 800,000
Warrants outstanding, term	9 years 1 month 6 days
Exercise price (in Dollars per share) | $ / shares	$ 30
Capital expenditure forecast (in millions)	$ 375,000,000
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series E Unvested Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.023
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series E Unvested Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series E Unvested Warrants | Measurement Input, Probability of Warrants Vesting
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.638
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series F Unvested Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value (in millions)	$ 600,000
Warrants outstanding, term	9 years 1 month 6 days
Exercise price (in Dollars per share) | $ / shares	$ 40
Capital expenditure forecast (in millions)	$ 500,000,000
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series F Unvested Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.023
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series F Unvested Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Series F Unvested Warrants | Measurement Input, Probability of Warrants Vesting
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.544

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details)	Mar. 31, 2022 $ / shares	May 17, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, term		10 years
Private Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price (in Dollars per share)	$ 11.50
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives, term	3 years
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivatives, term	7 years
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.024
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.560
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Probability Of Redemption Trigger
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.750
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, term	3 years 11 months 19 days
Exercise price (in Dollars per share)	$ 11.50
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.024
Level 3: Significant Unobservable Inputs | Fair Value, Nonrecurring | Private Warrants | Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and right outstanding, measurement input	0.640

Derivative Liability - Non-Co_3

Derivative Liability - Non-Controlling Redeemable Preferred Stock (Details) - USD ($)		Mar. 31, 2022	Dec. 31, 2021
Embedded Derivative [Line Items]
Derivative liability - non-controlling redeemable preferred shares	[1]	$ 433,000	$ 511,948
Other Long-term Liabilities
Embedded Derivative [Line Items]
Derivative liability - non-controlling redeemable preferred shares		$ 458,476	$ 511,948
[1]See Note 2.

Investment in Dreev (Details)

Investment in Dreev (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Investment Holdings [Line Items]
Consulting services (in Dollars)	$ 0	$ 0
Dreev
Investment Holdings [Line Items]
Company's equity ownership	13%

Account Receivables, Net (Detai

Account Receivables, Net (Details) - USD ($)		3 Months Ended
		Mar. 31, 2022	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Less: allowance for doubtful accounts		$ (63,188)	$ (63,188)
Accounts receivable	[1]	1,431,134	1,886,708
Allowance for doubtful accounts:
Balance December 31, 2021		(63,188)
Provision		0
Write-off		0
Recoveries		0
Balance March 31, 2022		(63,188)
Trade Accounts Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Trade receivables		$ 1,494,322	$ 1,949,896
[1]See Note 2.

Inventories (Details)

Inventories (Details)	3 Months Ended
	Mar. 31, 2022 USD ($) bus	Dec. 31, 2021 USD ($)
Inventory [Line Items]
Inventory, gross	$ 9,328,206	$ 11,118,188
Number of school buses delivered to company | bus	10
Number of years for buses to be delivered	1 year
Number of school buses were sold | bus	5
DC Chargers
Inventory [Line Items]
Inventory, gross	$ 7,431,300	7,687,598
AC Chargers
Inventory [Line Items]
Inventory, gross	204,687	232,920
Vehicles - School Buses
Inventory [Line Items]
Inventory, gross	1,620,000	3,180,000
Others
Inventory [Line Items]
Inventory, gross	$ 72,219	$ 17,670

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 693,044		$ 442,182
Less: Accumulated Depreciation		(120,545)		(85,988)
Property and equipment, net	[1]	572,499		356,194
Depreciation expense		25,975	$ 6,508
Computers & Servers
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		113,490		105,499
Vehicles
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		168,862		168,862
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		317,546		161,771
Others
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 93,146		$ 6,050
[1]See Note 2.

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Gross intangible asset	$ 2,091,556		$ 2,091,556
Amortization expense of intangible assets	34,860	$ 34,860
Finite-lived intangible assets, accumulated amortization	645,340		$ 610,480
Finite-lived intangible assets, net	$ 1,446,218
Acquire finite-lived intangible assets, weighted average useful life	10 years 7 months 6 days

Intangible Assets - Schedule of

Intangible Assets - Schedule of estimated future amortization expense amortizable intangible assets (Details)	Mar. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (remaining nine months)	$ 104,577
2023	139,437
2024	139,437
2025	139,437
2026	139,437
Thereafter	783,893
Total estimated future amortization expense	$ 1,446,218

Stockholders_ Equity (Details)

Stockholders’ Equity (Details)					3 Months Ended
	Apr. 23, 2021 $ / shares shares	Nov. 11, 2020 $ / shares shares	Nov. 11, 2020 USD ($) $ / shares shares	Feb. 19, 2020 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) class_of_stock $ / shares shares		Mar. 31, 2021 USD ($)	Dec. 31, 2021 $ / shares	May 17, 2021 USD ($) $ / shares shares
Stockholders' Equity [Line Items]
Number of classes of stock | class_of_stock					2
Authorized capital stock (in Shares) | shares					101,000,000
Common stock, shares authorized (in Shares) | shares					100,000,000
Common stock par value (in Dollars per share) | $ / shares					$ 0.0001			$ 0.0001
Preferred stock, shares authorized (in Shares) | shares					1,000,000
Preferred stock par value (in Dollars per share) | $ / shares					$ 0.0001
Warrants outstanding, term									10 years
Sale of units (in Shares) | shares	134,499
Purchase price (in Dollars per share) | $ / shares	$ 14.87								$ 50
Warrant Liability | $					$ 433,000
Fair value adjustments | $					4,776,000	[1],[2]	$ 421,830
Purchase agreement, authorized amount | $									$ 250,000,000
Grant date fair value of securities purchase agreement | $									$ 12,600,000
Stonepeak
Stockholders' Equity [Line Items]
Percent of warrants issued									90%
Evolve
Stockholders' Equity [Line Items]
Percent of warrants issued									10%
Unit Purchase Option
Stockholders' Equity [Line Items]
Percent of one share of common stock				10%
Shares issued (in Dollars per share) | $ / shares				$ 100
Exercisable units (in shares) | shares				316,250
Options exercisable (in Dollars per share) | $ / shares				$ 11.50
Aggregate exercise price | $				$ 3,636,875
Unit Purchase Option | Minimum
Stockholders' Equity [Line Items]
Right to registration, period				5 years
Unit Purchase Option | Maximum
Stockholders' Equity [Line Items]
Right to registration, period				7 years
Investor
Stockholders' Equity [Line Items]
Common stock shares purchase (in Shares) | shares			1,425,000
Purchase price per share value (in Dollars per share) | $ / shares		$ 10	$ 10
PIPE
Stockholders' Equity [Line Items]
Sale of units (in Shares) | shares		1.9
Aggregate purchase price of common stock (in Dollars) | $			$ 14,250,000
Purchase price (in Dollars per share) | $ / shares		$ 11.50	$ 11.50
IPO | Newborn
Stockholders' Equity [Line Items]
Number of warrants per unit (in Shares) | shares				1
Percent of one share of common stock				50%
Class of warrant or right, number of securities called by each warrant | shares				1
Private Placement
Stockholders' Equity [Line Items]
Fair value adjustments | $					$ 433,000
Private Placement | Newborn
Stockholders' Equity [Line Items]
Number of warrants per unit (in Shares) | shares				1
Stonepeak/Evolve Warrants - series B
Stockholders' Equity [Line Items]
Warrants outstanding, grant date fair value | $									$ 12,800,000
Exercise price (in Dollars per share) | $ / shares					$ 10
Stonepeak/Evolve Warrants - series C
Stockholders' Equity [Line Items]
Warrants outstanding, grant date fair value | $									5,600,000
Exercise price (in Dollars per share) | $ / shares					15
Stonepeak/Evolve Warrants - series D
Stockholders' Equity [Line Items]
Warrants outstanding, grant date fair value | $									4,800,000
Exercise price (in Dollars per share) | $ / shares					20
Stonepeak/Evolve Warrants - series E
Stockholders' Equity [Line Items]
Warrants outstanding, grant date fair value | $									3,800,000
Exercise price (in Dollars per share) | $ / shares					30
Stonepeak/Evolve Warrants - series F
Stockholders' Equity [Line Items]
Warrants outstanding, grant date fair value | $									$ 3,200,000
Exercise price (in Dollars per share) | $ / shares					$ 40
Warrants
Stockholders' Equity [Line Items]
Sale of units (in Shares) | shares				5,750,000
Warrants | Private Placement
Stockholders' Equity [Line Items]
Aggregate share purchase (in Shares) | shares				272,500
Stonepeak Warrants | Securities Purchase Agreement
Stockholders' Equity [Line Items]
Percent of warrants issued									90%
Evolve Warrants | Securities Purchase Agreement
Stockholders' Equity [Line Items]
Percent of warrants issued									10%
Stonepeak/Evolve Warrants - series B
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares) | shares									2,000,000
Exercise price (in Dollars per share) | $ / shares									$ 10
Stonepeak/Evolve Warrants - series C
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares) | shares									1,000,000
Percent of warrants vested upon issuance									50%
Additional capital expenditure to trigger exercise of nonvested warrants | $									$ 125,000,000
Percent of warrants vested upon additional capital expenditures									50%
Exercise price (in Dollars per share) | $ / shares									$ 15
Stonepeak/Evolve Warrants - series D
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares) | shares									1,000,000
Percent of warrants vested upon issuance									50%
Additional capital expenditure to trigger exercise of nonvested warrants | $									$ 250,000,000
Percent of warrants vested upon additional capital expenditures									50%
Exercise price (in Dollars per share) | $ / shares									$ 20
Stonepeak/Evolve Warrants - series E
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares) | shares									1,000,000
Percent of warrants vested upon issuance									50%
Additional capital expenditure to trigger exercise of nonvested warrants | $									$ 375,000,000
Percent of warrants vested upon additional capital expenditures									50%
Exercise price (in Dollars per share) | $ / shares									$ 30
Stonepeak/Evolve Warrants - series F
Stockholders' Equity [Line Items]
Number of securities called by warrants (in shares) | shares									1,000,000
Percent of warrants vested upon issuance									50%
Additional capital expenditure to trigger exercise of nonvested warrants | $									$ 500,000,000
Percent of warrants vested upon additional capital expenditures									50%
Exercise price (in Dollars per share) | $ / shares									$ 40
[1](1) See Note 2.[2]See Note 2.

Stockholders_ Equity - Schedule

Stockholders’ Equity - Schedule of common stock issuable upon exercise of warrants outstanding (Details)	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	10,365,000
Number of Warrants Exercisable (in shares)	8,365,000
Public Warrants
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	2,875,000
Number of Warrants Exercisable (in shares)	2,875,000
Exercise price (in Dollars per share) | $ / shares	$ 11.50
Private Warrants
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	136,250
Number of Warrants Exercisable (in shares)	136,250
Exercise price (in Dollars per share) | $ / shares	$ 11.50
PIPE Warrants
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,353,750
Number of Warrants Exercisable (in shares)	1,353,750
Exercise price (in Dollars per share) | $ / shares	$ 11.50
Stonepeak/Evolve Warrants - series B
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	2,000,000
Number of Warrants Exercisable (in shares)	2,000,000
Exercise price (in Dollars per share) | $ / shares	$ 10
Stonepeak/Evolve Warrants - series C
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,000,000
Number of Warrants Exercisable (in shares)	500,000
Exercise price (in Dollars per share) | $ / shares	$ 15
Stonepeak/Evolve Warrants - series D
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,000,000
Number of Warrants Exercisable (in shares)	500,000
Exercise price (in Dollars per share) | $ / shares	$ 20
Stonepeak/Evolve Warrants - series E
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,000,000
Number of Warrants Exercisable (in shares)	500,000
Exercise price (in Dollars per share) | $ / shares	$ 30
Stonepeak/Evolve Warrants - series F
Stockholders’ Equity (Details) - Schedule of common stock issuable upon exercise of warrants outstanding [Line Items]
Number of Warrants (in shares)	1,000,000
Number of Warrants Exercisable (in shares)	500,000
Exercise price (in Dollars per share) | $ / shares	$ 40

Stock Option Plan - Narrative (

Stock Option Plan - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based option modified (in Shares)			1,640,000
Increase decrease exercise price (in Dollars per share)			$ 0.60
Incremental compensation cost (in Dollars)			$ 246,000
Unrecognized compensation costs, period of recognition	2 years 11 months 23 days
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional compensation expense	$ 19,699	$ 0
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to nonvested restricted stock (in Dollars)	$ 2,200,843
Unrecognized compensation costs, period of recognition	1 year 4 months 24 days
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate of common shares (in Shares)	3,300,000
Option contractual life	10 years
Issuance of common stock available for future (in Shares)	1,321,374
Weighted average grant date fair value of options granted during period (in Dollars per share)	$ 3.58
2020 Plan | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option vesting period	4 years
2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options granted during period (in Dollars per share)	$ 0

Stock Option Plan - Schedule of

Stock Option Plan - Schedule of stock-based compensation expense for stock options (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 822,106	$ 262,105
Restricted stock
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	613,839	0
Options and Restricted Stock
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 1,435,945	$ 262,105

Stock Option Plan - Schedule _2

Stock Option Plan - Schedule of black-scholes option pricing model to estimate the fair value of stock options (Details)	3 Months Ended
	Mar. 31, 2022
2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options (in years)	6 years 1 month 6 days
Dividend yield	0%
Risk-free interest rate	2%
Volatility	54.40%
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options (in years)	6 years 1 month 6 days
Dividend yield	0%
Risk-free interest rate	2%
Volatility	54.40%

Stock Option Plan - Schedule _3

Stock Option Plan - Schedule of stock option activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
2010 Plan
Shares
Beginning balance (in Shares)	1,035,035
Granted, (in Shares)	0
Exercised (in Shares)	0
Forfeited (in Shares)	0
Expired/Cancelled (in Shares)	(5,310)
Ending balance (in Shares)	1,029,725	1,035,035
Options exercisable (in Shares)	857,024
Options vested (in Shares)	857,024
Weighted- Average Exercise Price per Share($)
Beginning balance (in Dollars per share)	$ 3.21
Granted (in Dollars per share)	0
Exercised (in Dollars per share)	0
Forfeited (in Dollars per share)	0
Expired/Cancelled (in Dollars per share)	1.37
Ending balance (in Dollars per share)	3.22	$ 3.21
Options exercisable (in Dollars per share)	2.43
Options vested (in Dollars per share)	$ 2.43
Weighted- Average Remaining Contractual Term (Years)
Outstanding, weighted-average remaining contractual term	5 years 8 months 8 days	5 years 10 months 24 days
Options exercisable, weighted average remaining contractual term	5 years 1 month 20 days
Options vested, weighted average remaining contractual term	5 years 1 month 20 days
Aggregate Intrinsic Value($)
Outstanding	$ 5,649,500	$ 5,688,201
Exercisable	5,344,262
Vested	$ 5,344,262
2020 Plan
Shares
Beginning balance (in Shares)	1,602,850
Granted, (in Shares)	106,000
Exercised (in Shares)	0
Forfeited (in Shares)	0
Expired/Cancelled (in Shares)	0
Ending balance (in Shares)	1,708,850	1,602,850
Options exercisable (in Shares)	330,062
Options vested (in Shares)	330,062
Weighted- Average Exercise Price per Share($)
Beginning balance (in Dollars per share)	$ 13.18
Granted (in Dollars per share)	6.77
Exercised (in Dollars per share)	0
Forfeited (in Dollars per share)	0
Expired/Cancelled (in Dollars per share)	0
Ending balance (in Dollars per share)	12.78	$ 13.18
Options exercisable (in Dollars per share)	13.70
Options vested (in Dollars per share)	$ 13.70
Weighted- Average Remaining Contractual Term (Years)
Outstanding, weighted-average remaining contractual term	9 years 25 days	9 years 3 months 7 days
Granted, weighted average remaining contractual term	9 years 10 months 9 days
Aggregate Intrinsic Value($)
Outstanding	$ 252,560	$ 46,920
Exercisable	0
Vested	$ 0

Stock Option Plan - Schedule _4

Stock Option Plan - Schedule of other share based compensation information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement [Abstract]
Proceeds from exercise of stock options	$ 0	$ 0
Unrecognized compensation costs	$ 9,987,990
Unrecognized compensation costs, period of recognition	2 years 11 months 23 days

Stock Option Plan - Schedule _5

Stock Option Plan - Schedule of nonvested restricted stock units (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in Shares) | shares	353,817
Granted (in Shares) | shares	27,478
Vested/Release (in Shares) | shares	(30,370)
Cancelled/Forfeited (in Shares) | shares	0
Ending balance (in Shares) | shares	350,925
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance (in Dollars per share) | $ / shares	$ 11
Granted (in Dollars per share) | $ / shares	10.15
Vested/Release (in Dollars per share) | $ / shares	13.79
Cancelled/Forfeited (in Dollars per share) | $ / shares	0
Ending balance (in Dollars per share) | $ / shares	$ 10.70

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022		Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ 0	[1]	$ 0
Effective tax rate	0%		(0.10%)
[1]See Note 2.

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022		Mar. 31, 2021
Earnings Per Share [Abstract]
Net loss attributable to Nuvve common stockholders, basic	$ (4,855,809)	[1]	$ (5,361,720)
Net loss attributable to Nuvve common stockholders, diluted	$ (4,855,809)		$ (5,361,720)
Weighted-average shares used in computing net loss per share attributable to Nuvve Holding Corp. common stockholders, basic (in Shares)	18,864,374	[1]	10,408,080
Weighted-average shares used in computing net loss per share attributable to Nuvve Holding Corp. common stockholders, diluted (in Shares)	18,864,374	[1]	10,408,080
Net loss per share attributable to Nuvve common stockholders, basic (in Dollars per share)	$ (0.26)	[1]	$ (0.52)
Net loss per share attributable to Nuvve common stockholders, diluted (in Dollars per share)	$ (0.26)	[1]	$ (0.52)
[1]See Note 2.

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Attributable to Nuvve common stockholders (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	19,019,626	5,788,228
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	2,773,734	1,415,355
Nonvested Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	880,892	7,873
Public Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	2,875,000	2,875,000
Private Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	136,250	136,250
PIPE
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	1,353,750	1,353,750
Stonepeak Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	6,000,000	0
Stonepeak Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share (in Shares)	5,000,000	0

Related Parties (Details)

Related Parties (Details) - USD ($)		3 Months Ended
	Apr. 23, 2021	Mar. 31, 2022	Mar. 31, 2021	May 17, 2021
Related Party Transaction [Line Items]
Revenue from related parties		$ 28,000	$ 147,620
Accounts receivable, related parties		$ 28,000
Purchased shares (in Shares)	134,499
Purchase price (in Dollars per share)	$ 14.87			$ 50
Amount of purchase	$ 2,000,000
Chief Operating Officer
Related Party Transaction [Line Items]
Purchased shares (in Shares)	26,900

Leases - Lease cost (Details)

Leases - Lease cost (Details) - USD ($)		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Right-of-use operating assets	[1]	$ 3,397,270		$ 3,483,042
Finance lease assets		23,550
Operating and finance lease right-of-use assets		$ 3,420,820
Finance lease, right-of-use asset, statement of financial position [extensible list]		Property and equipment, net
Operating lease liabilities - current	[1]	$ 254,057		41,513
Operating lease liabilities - noncurrent	[1]	3,319,734		$ 3,441,642
Finance lease liabilities - current		7,444
Finance lease liabilities - noncurrent		17,283
Total lease obligations		$ 3,598,518
Operating lease, liability, noncurrent, statement of financial position, extensible list		Operating lease liabilities - noncurrent
Finance lease, liability, current, statement of financial position, extensible list		Other liabilities
Finance lease, liability, noncurrent, statement of financial position, extensible list		Other long-term liabilities
Total lease expense		$ 183,099	$ 58,431
Selling, General, and Administrative Expenses
Lessee, Lease, Description [Line Items]
Operating lease expense		176,520	58,431
Amortization of finance lease assets		5,940	0
Interest Expense
Lessee, Lease, Description [Line Items]
Interest expense		$ 639	$ 0
[1]See Note 2.

Leases - Schedule of operating

Leases - Schedule of operating lease liability maturity (Details)	Mar. 31, 2022 USD ($)
Operating Lease
2022	$ 125,784
2023	514,377
2024	529,807
2025	545,703
2026	562,074
Thereafter	3,017,861
Total lease payments	5,295,606
Less: interest	(1,721,815)
Total lease obligations	3,573,791
Finance Lease
2022	5,583
2023	7,444
2024	7,444
2025	7,444
2026	0
Thereafter	1,861
Total lease payments	29,776
Less: interest	(5,049)
Total lease obligations	$ 24,727

Leases - Lease term, discount r

Leases - Lease term, discount rate, and other information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022		Mar. 31, 2021
Weighted-average remaining lease terms (in years):
Operating lease	9 years 8 months 12 days
Finance lease	4 years
Weighted-average discount rate:
Operating lease	7.80%
Finance lease	7.80%
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 62,269		$ 0
Operating cash flows from finance leases	639		0
Financing cash flows from finance leases	2,073	[1]	0
Leased assets obtained in exchange for new finance lease liabilities	23,550		0
Leased assets obtained in exchange for new operating lease liabilities	$ 0		$ 0
[1](1) See Note 2.

Leases - Maturity analysis of m

Leases - Maturity analysis of main office lease (Details)	Mar. 31, 2022 USD ($)	Nov. 03, 2021 ft²
Lessee, Lease, Description [Line Items]
2022	$ 125,784
2023	514,377
2024	529,807
2025	545,703
2026	562,074
Thereafter	3,017,861
Total lease payments	5,295,606
Main Office Lease
Lessee, Lease, Description [Line Items]
Net rentable area | ft²		4,811
Operating lease, fixed percent increase in rental payment		3%
2022	146,495
2023	256,785
2024	264,488
2025	272,423
2026	280,596
Thereafter	1,507,106
Total lease payments	$ 2,727,893

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details)				3 Months Ended	12 Months Ended
	Dec. 27, 2021 USD ($) dCCharger	Oct. 05, 2020 USD ($)	Nov. 17, 2017 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 20, 2021 USD ($) dCCharger	Mar. 31, 2021 USD ($)	Sep. 01, 2016 USD ($)
Other Commitments [Line Items]
Installment amount				$ 100,000			$ 100,000	$ 400,000
Related party debt outstanding				$ 166,667
Property expire				20 years
Royalty expense, aggregate amount under agreement				$ 700,000
Royalty expense				0	$ 0
Acquisition costs, amortization period			15 years
Investment				270,000
Legal fees, aggregate amount authorized		$ 96,000
Legal fees				$ 0
Purchase obligation, number of DC chargers | dCCharger						250
Purchase Obligation						$ 13,200,000
Purchase obligation, DC chargers received | dCCharger	80
Purchase obligation, purchases	$ 3,100,000
IP Acquisition Agreement
Other Commitments [Line Items]
Asset acquisition, upfront payment			$ 500,000
Asset acquisition, equity consideration transferred			1,491,556
Asset acquisition, consideration transferred			1,991,556
Royalties payments			$ 7,500,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of milestone event (Details)	3 Months Ended
	Mar. 31, 2022 USD ($)
Other Commitments [Line Items]
Milestone payment amount	$ 7,500,000
10000
Other Commitments [Line Items]
Milestone payment amount	500,000
20000
Other Commitments [Line Items]
Milestone payment amount	750,000
40000
Other Commitments [Line Items]
Milestone payment amount	750,000
60000
Other Commitments [Line Items]
Milestone payment amount	750,000
80000
Other Commitments [Line Items]
Milestone payment amount	750,000
100000
Other Commitments [Line Items]
Milestone payment amount	1,000,000
200000
Other Commitments [Line Items]
Milestone payment amount	1,000,000
250000
Other Commitments [Line Items]
Milestone payment amount	$ 2,000,000

Non-Controlling Interest - Narr

Non-Controlling Interest - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Noncontrolling Interest [Line Items]
Temporary equity, shares authorized (in Shares)	1,000,000
Temporary equity, par value (in Dollars per share)	$ 0
Temporary equity, shares issued (in Shares)	3,138	3,138
Temporary equity, shares outstanding (in Shares)	3,138	3,138
Less: Non-controlling redeemable preferred shares - embedded derivatives	$ 0
Redeemable noncontrolling interest, equity, carrying amount	$ 3,138,000
Accretion period (in years)	7 years
Redeemable non controlling interests
Noncontrolling Interest [Line Items]
Redeemable noncontrolling interest, equity, carrying amount	$ 3,063,365	$ 2,901,899
Accretion value	$ 161,466
Levo Mobility LLC | Series B Preferred Stock
Noncontrolling Interest [Line Items]
Temporary equity, shares authorized (in Shares)	1,000,000
Temporary equity, dividend rate, percentage	8%
Temporary equity, par value (in Dollars per share)	$ 1,000
Temporary equity, accretion of dividends	$ 126,775
Temporary equity, shares issued (in Shares)	3,138
Temporary equity, shares outstanding (in Shares)	3,138
Redeemable noncontrolling interest, equity, fair value	$ 3,138,000

Non-Controlling Interest - Seri

Non-Controlling Interest - Series B Preferred Stock (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Noncontrolling Interest [Line Items]
Temporary equity, shares authorized (in Shares)	1,000,000
Temporary equity, shares outstanding (in Shares)	3,138	3,138
Temporary equity, shares issued (in Shares)	3,138	3,138
Temporary equity, par value (in Dollars per share)	$ 0
Temporary equity, liquidation preference	$ 3,264,775
Series B Preferred Stock | Levo Mobility LLC
Noncontrolling Interest [Line Items]
Temporary equity, shares authorized (in Shares)	1,000,000
Temporary equity, shares outstanding (in Shares)	3,138
Temporary equity, shares issued (in Shares)	3,138
Temporary equity, par value (in Dollars per share)	$ 1,000
Redeemable noncontrolling interest, equity, fair value	$ 3,138,000
Temporary equity, accretion of dividends	126,775
Temporary equity, liquidation preference	$ 3,264,775

Non-Controlling Interest - Non-

Non-Controlling Interest - Non-controlling interests presented as a separate component of stockholders’ equity (Details) - USD ($)		3 Months Ended
		Mar. 31, 2022		Mar. 31, 2021	Dec. 31, 2021
Noncontrolling Interest [Line Items]
Add: Net loss attributable to non-controlling interests		$ (100,933)	[1]	$ 0
Preferred dividends - non-controlling interest	[2]	64,015
Non-controlling interests	[3]	(2,828,047)			$ (2,501,633)
Levo Mobility LLC
Noncontrolling Interest [Line Items]
Add: Net loss attributable to non-controlling interests		(100,933)
Preferred dividends - non-controlling interest		64,015
Preferred share Accretion adjustment		161,466
Non-controlling interests		$ (326,414)
[1]See Note 2.[2]See Note 2[3]See Note 2.

Non-Controlling Interest - Cond

Non-Controlling Interest - Condensed consolidated statements of operations (Details)	3 Months Ended
	Mar. 31, 2022 USD ($)
Levo Mobility LLC
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests	$ (100,933)

Non-Controlling Interest - Rede

Non-Controlling Interest - Redeemable noncontrolling interest reconciliation (Details)	3 Months Ended
	Mar. 31, 2022 USD ($)
Increase (Decrease) in Temporary Equity [Roll Forward]
Ending balance	$ 3,138,000
Redeemable non controlling interests
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	2,901,899
Preferred share Accretion adjustment	161,466
Ending balance	$ 3,063,365

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event	1 Months Ended
	Apr. 30, 2022 USD ($) ft²
Subsequent Event [Line Items]
Net area subleased | ft²	4,811
Main Office Lease
Subsequent Event [Line Items]
Sublease monthly rental income | $	$ 2,250